Candidate Compounds Covid19

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
(26 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 26: Zeile 26:
 
*[[Target Complement system]]
 
*[[Target Complement system]]
 
*[[Target Extracellular traps]]
 
*[[Target Extracellular traps]]
 +
*[[Target Neurophils]]
 +
*[[Target Mast cells]] and kinins
 +
*[[TGF beta]]
 +
*[[Immunosuppressants]]
 
*[[Anticoagulant in covid19]]
 
*[[Anticoagulant in covid19]]
 
*[[Antioxidants]]
 
*[[Antioxidants]]
 +
*[[HIF-EPO-Iron]]
 
*[[Stem cells]]
 
*[[Stem cells]]
 
*[[MDSC cells]]
 
*[[MDSC cells]]
 
*[[Interferons]]
 
*[[Interferons]]
 +
*[[cAMP cGMP PDE NO]]
 +
*[[TRPV* channels]]
 +
*[[Retinoids]]
 +
*[[Protease inhibitors]]
 +
*[[Tyrosine kinase inhibitors]]
 +
*[[Antineoplastic agents, traditional]]
 +
*[[Mouthrinses]]
 +
*[[Adenosinergic signaling]]
 +
*[[Purinergic signaling]]
 +
*[[Nicotinergic signaling]]
  
  
 
*[[other single compounds]]
 
*[[other single compounds]]
*[[Retargeted single compounds]]
+
*[[Retargeted Psychopharm]]
 
*[[Hydroxychloroquine]]  
 
*[[Hydroxychloroquine]]  
 
*
 
*
Zeile 43: Zeile 58:
 
*[[AV Lopinavir]]
 
*[[AV Lopinavir]]
 
*[[AV Ivermectin]]
 
*[[AV Ivermectin]]
 +
*[[AV Arabidol]]
 +
*[[AV Favipiravir]]
  
 
+
*[[Antibiotics]]
  
  
Zeile 51: Zeile 68:
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Selenium]]
 
*[[Anorganic nutrients Zinc]]
 
*[[Anorganic nutrients Zinc]]
 +
*[[Anorganic nutrients Lithium]]
 +
*[[Anorganic nutrients Copper]]
 +
*[[Anorganic nutrients Bismuth]]
 
*[[Nutrition, general]]
 
*[[Nutrition, general]]
 
*[[Exercise, Vibration]]
 
*[[Exercise, Vibration]]
Zeile 61: Zeile 81:
 
*[[Antidiabetic compounds, any]]
 
*[[Antidiabetic compounds, any]]
 
*[[RSP - On RAS drugs]]
 
*[[RSP - On RAS drugs]]
 +
*[[RSP - On NSAIDs]]
  
 
*[[Reconvalescent blood products, Passive vaccine]]  
 
*[[Reconvalescent blood products, Passive vaccine]]  
Zeile 70: Zeile 91:
 
*[[Active vaccine]]  
 
*[[Active vaccine]]  
  
===008===
+
*[[Treatment other concepts]]
{{tp|p=32458400|t=2020. Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19.|pdf=|usr=008}}
+
----
 
+
{{tp|p=32401611|t=2020. The pulmonary-proteoliposome as a new therapeutic approach for Coronaviruses.|pdf=|usr=008}}
+
 
+
{{tp|p=32483527|t=2020. Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a.|pdf=|usr=008}}
+
 
+
 
+
 
+
{{tp|p=32519258|t=2020. BCG Vaccination Policy and Protection Against COVID-19.|pdf=|usr=008}}
+
{{tp|p=32419838|t=2020. Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment.|pdf=|usr=008}}
+
 
+
{{tp|p=32418190|t=2020. Early experience with remdesivir in SARS-CoV-2 pneumonia.|pdf=|usr=008}}
+
{{tp|p=32382744|t=2020. Anti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32395606|t=2020. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.|pdf=|usr=008}}
+
{{tp|p=32413736|t=2020. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids.|pdf=|usr=008}}
+
{{tp|p=32389723|t=2020. Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.|pdf=|usr=008}}
+
{{tp|p=32479893|t=2020. Ivermectin: repurposing a multipurpose drug for Venezuela's humanitarian crisis.|pdf=|usr=008}}
+
{{tp|p=32454071|t=2020. Is teicoplanin a complementary treatment option for COVID-19? The question remains.|pdf=|usr=008}}
+
{{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
+
{{tp|p=32522674|t=2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32502524|t=2020. Tocilizumab administration in a refractory case of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32534189|t=2020. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.|pdf=|usr=008}}
+
{{tp|p=32534188|t=2020. Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A global pandemic and treatments strategies.|pdf=|usr=008}}
+
{{tp|p=32534187|t=2020. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.|pdf=|usr=008}}
+
{{tp|p=32470577|t=2020. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.|pdf=|usr=008}}
+
{{tp|p=32534094|t=2020. Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R)).|pdf=|usr=008}}
+
{{ttp|p=32398962|t=2020. A potential treatment of COVID-19 with TGF-beta blockade.|pdf=|usr=008}}
+
{{tp|p=32435920|t=2020. Lithium's antiviral effects: a potential drug for CoViD-19 disease?|pdf=|usr=008}}
+
{{tp|p=32382873|t=2020. Covid-19 and drug therapy, what we learned.|pdf=|usr=008}}
+
{{tp|p=32460369|t=2020. Non-steroidal anti-inflammatory drugs in management of COVID-19; A systematic review on current evidence.|pdf=|usr=008}}
+
{{tp|p=32412158|t=2020. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19.|pdf=|usr=008}}
+
{{tp|p=32531935|t=2020. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors.|pdf=|usr=008}}
+
{{tp|p=32479865|t=2020. Lack of antiviral activity of darunavir against SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32470602|t=2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.|pdf=|usr=008}}
+
 
+
{{tp|p=32425638|t=2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.|pdf=|usr=008}}
+
{{tp|p=32522597|t=2020. Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients.|pdf=|usr=008}}
+
{{tp|p=32502659|t=2020. Potential role of statins in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32521619|t=2020. Redox-Modulating Agents in the Treatment of Viral Infections.|pdf=|usr=008}}
+
{{tp|p=32461554|t=2020. Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32327922|t=2020. The 4 D's of Pellagra and Progress.|pdf=|usr=008}}
+
{{tp|p=32447429|t=2020. Trials and tribulations: so many potential treatments, so few answers.|pdf=|usr=008}}
+
{{tp|p=32483523|t=2020. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review.|pdf=|usr=008}}
+
{{tp|p=32426222|t=2020. The Ethics of COVID-19 Clinical Trials: New Considerations in a Controversial Area.|pdf=|usr=008}}
+
 
+
{{tp|p=32488835|t=2020. Deep Learning Based Drug Screening for Novel Coronavirus 2019-nCov.|pdf=|usr=008}}
+
 
+
{{tp|p=32458206|t=2020. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?|pdf=|usr=008}}
+
{{tp|p=32411575|t=2020. Malnutrition Care during the COVID-19 Pandemic: Considerations for Registered Dietitian Nutritionists Evidence Analysis Center.|pdf=|usr=008}}
+
{{tp|p=32479759|t=2020. Successful use of methylprednisolone for treating severe COVID-19.|pdf=|usr=008}}
+
{{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
+
{{tp|p=32437739|t=2020. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32533071|t=2020. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.|pdf=|usr=008}}
+
{{tp|p=32407513|t=2020. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?|pdf=|usr=008}}
+
 
+
{{tp|p=32417899|t=2020. Favipiravir, an antiviral for COVID-19?|pdf=|usr=008}}
+
 
+
{{tp|p=32527713|t=2020. In Silico computational screening of Kabasura Kudineer - Official Siddha Formulation and JACOM against SARS-CoV-2 spike protein.|pdf=|usr=008}}
+
{{tp|p=32397940|t=2020. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors.|pdf=|usr=008}}
+
{{tp|p=32397906|t=2020. Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase.|pdf=|usr=008}}
+
{{tp|p=32396773|t=2020. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent.|pdf=|usr=008}}
+
{{tp|p=32396771|t=2020. Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary.|pdf=|usr=008}}
+
{{tp|p=32396769|t=2020. Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach.|pdf=|usr=008}}
+
{{tp|p=32394467|t=2020. A global treatments for coronaviruses including COVID-19.|pdf=|usr=008}}
+
{{tp|p=32474331|t=2020. Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease.|pdf=|usr=008}}
+
{{tp|p=32526460|t=2020. A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.|pdf=|usr=008}}
+
 
+
{{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}}
+
{{tp|p=32489508|t=2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?|pdf=|usr=008}}
+
{{tp|p=32425662|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=008}}
+
{{tp|p=32425661|t=2020. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32384202|t=2020. Home-based training strategy to maintain muscle function in older adults with diabetes during COVID-19 confinement.|pdf=|usr=008}}
+
 
+
{{tp|p=32388906|t=2020. Do novel drugs for diabetes help in COVID-19? Another brick in the wall?|pdf=|usr=008}}
+
{{tp|p=32514902|t=2020. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.|pdf=|usr=008}}
+
{{tp|p=32495299|t=2020. COVID-19: is there a link between the course of infection and pharmacological agents in diabetes?|pdf=|usr=008}}
+
{{tp|p=32386438|t=2020. 'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient.|pdf=|usr=008}}
+
{{tp|p=32398164|t=2020. Drug repurposing against COVID-19: focus on anticancer agents.|pdf=|usr=008}}
+
{{tp|p=32421102|t=2020. Exploring the Active Compounds of Traditional Mongolian Medicine in Intervention of Novel Coronavirus (COVID-19) Based on Molecular Docking Method.|pdf=|usr=008}}
+
{{tp|p=32474141|t=2020. Vitamin D deficiency and the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32509284|t=2020. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.|pdf=|usr=008}}
+
{{tp|p=32395245|t=2020. Hypertonic saline nasal irrigation and gargling should be considered as a treatment option for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32360293|t=2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?|pdf=|usr=008}}
+
{{tp|p=32389783|t=2020. Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32473230|t=2020. Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.|pdf=|usr=008}}
+
{{tp|p=32422152|t=2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.|pdf=|usr=008}}
+
{{tp|p=32417314|t=2020. Corticosteroid use in selected patients with severe acute respiratory distress syndrome related to COVID-19.|pdf=|usr=008}}
+
{{tp|p=32283144|t=2020. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.|pdf=|usr=008}}
+
{{tp|p=32283143|t=2020. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32451258|t=2020. Can complementary and alternative medicines be beneficial in the treatment of COVID-19 through improving immune system function?|pdf=|usr=008}}
+
 
+
{{tp|p=32458279|t=2020. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.|pdf=|usr=008}}
+
{{tp|p=32533263|t=2020. Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.|pdf=|usr=008}}
+
{{tp|p=32405780|t=2020. Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.|pdf=|usr=008}}
+
 
+
{{tp|p=32383582|t=2020. When the Others Become Us: A Chemist's Perspective of the COVID-19 Outbreak in Italy.|pdf=|usr=008}}
+
{{tp|p=32432466|t=2020. Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32402186|t=2020. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.|pdf=|usr=008}}
+
{{tp|p=32428392|t=2020. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease.|pdf=|usr=008}}
+
{{tp|p=32478500|t=2020. COVID-19 and Other Pandemics: How Might They Be Prevented?|pdf=|usr=008}}
+
{{tp|p=32519842|t=2020. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic.|pdf=|usr=008}}
+
{{tp|p=32469114|t=2020. An update on ACE2 amplification and its therapeutic potential.|pdf=|usr=008}}
+
 
+
{{tp|p=32350686|t=2020. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.|pdf=|usr=008}}
+
{{tp|p=32454090|t=2020. The preventive strategy for pandemics in the elderly is to collect in advance samples & data to counteract chronic inflammation (inflammaging).|pdf=|usr=008}}
+
{{tp|p=32534451|t=2020. Microdose lithium reduces cellular senescence in human astrocytes - a potential pharmacotherapy for COVID-19?|pdf=|usr=008}}
+
{{tp|p=32489694|t=2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?|pdf=|usr=008}}
+
{{tp|p=32489692|t=2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.|pdf=|usr=008}}
+
{{tp|p=32402109|t=2020. Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity-authors' reply.|pdf=|usr=008}}
+
{{tp|p=32402107|t=2020. Letter: low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity.|pdf=|usr=008}}
+
{{tp|p=32402098|t=2020. Letter: does vitamin D have a potential role against COVID-19? Authors' reply.|pdf=|usr=008}}
+
 
+
{{tp|p=32532620|t=2020. Opportunities and challenges of traditional Chinese medicine going abroad for COVID-19 treatment.|pdf=|usr=008}}
+
{{tp|p=32516203|t=2020. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.|pdf=|usr=008}}
+
{{tp|p=32406904|t=2020. Clinical trials: management of investigational products during the coronavirus (COVID-19) pandemic.|pdf=|usr=008}}
+
 
+
{{tp|p=32479920|t=2020. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32310688|t=2020. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity.|pdf=|usr=008}}
+
{{tp|p=32432923|t=2020. Reply to Jakovac: About COVID-19 and vitamin D.|pdf=|usr=008}}
+
{{tp|p=32519895|t=2020. Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?|pdf=|usr=008}}
+
{{tp|p=32519894|t=2020. Heparin as a Therapy for COVID-19: Current Evidence and Future Possibilities.|pdf=|usr=008}}
+
{{tp|p=32519892|t=2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.|pdf=|usr=008}}
+
{{tp|p=32297590|t=2020. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32499129|t=2020. Immunotherapies for COVID-19: Restoring the immunity could be the priority.|pdf=|usr=008}}
+
{{tp|p=32315803|t=2020. Preliminary therapeutic drug monitoring data of beta-lactams in critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
+
{{tp|p=32505720|t=2020. Positive Outcome in a COVID-19 patient with Common Variable Immunodeficiency after IVIG.|pdf=|usr=008}}
+
{{tp|p=32534022|t=2020. COVID-19 and allergen immunotherapy: theoretical benefits invite to adjustments in practice recommendations.|pdf=|usr=008}}
+
{{tp|p=32534944|t=2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.|pdf=|usr=008}}
+
{{tp|p=32473642|t=2020. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.|pdf=|usr=008}}
+
{{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
+
 
+
{{tp|p=32436029|t=2020. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome.|pdf=|usr=008}}
+
 
+
{{tp|p=32422065|t=2020. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=008}}
+
{{tp|p=32489437|t=2020. Clinical trials for coronavirus disease 2019: What is being evaluated and what is not.|pdf=|usr=008}}
+
{{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}}
+
{{tp|p=32440665|t=2020. Cross-Protection Induced by Encephalitis Vaccines against COVID-19 Might be a Reason for Relatively Lower Mortality Rate in Some Countries.|pdf=|usr=008}}
+
 
+
{{tp|p=32493626|t=2020. S1 Subunit and Host Proteases as Potential Therapeutic Avenues for the Treatment of COVID-19.|pdf=|usr=008}}
+
{{tp|p=32482373|t=2020. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32439198|t=2020. Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.|pdf=|usr=008}}
+
{{tp|p=32345532|t=2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.|pdf=|usr=008}}
+
{{tp|p=32399097|t=2020. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399096|t=2020. State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399095|t=2020. State-of-the-art tools to identify druggable protein ligand of SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32399094|t=2020. Statins and the COVID-19 main protease: in silico evidence on direct interaction.|pdf=|usr=008}}
+
{{tp|p=32399093|t=2020. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32514689|t=2020. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.|pdf=|usr=008}}
+
 
+
{{tp|p=32446195|t=2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics.|pdf=|usr=008}}
+
{{tp|p=32361193|t=2020. Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection.|pdf=|usr=008}}
+
{{tp|p=32399655|t=2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.|pdf=|usr=008}}
+
{{tp|p=32470547|t=2020. Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost.|pdf=|usr=008}}
+
{{tp|p=32440566|t=2020. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32458149|t=2020. Can Zn Be a Critical Element in COVID-19 Treatment?|pdf=|usr=008}}
+
{{tp|p=32532623|t=2020. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.|pdf=|usr=008}}
+
{{tp|p=32426388|t=2020. Computation screening of narcissoside a glycosyloxyflavone for potential novel coronavirus 2019 (COVID-19) inhibitor.|pdf=|usr=008}}
+
{{tp|p=32426387|t=2020. Artificial intelligence approach fighting COVID-19 with repurposing drugs.|pdf=|usr=008}}
+
{{tp|p=32534226|t=2020. Monoclonal antibody as a potential anti-COVID-19.|pdf=|usr=008}}
+
{{tp|p=32410772|t=2020. Emerging pharmacotherapies for COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32519753|t=2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.|pdf=|usr=008}}
+
 
+
{{tp|p=32383371|t=2020. Perspectives of Immune Therapy in Coronavirus Disease 2019.|pdf=|usr=008}}
+
{{tp|p=32508168|t=2020. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review.|pdf=|usr=008}}
+
{{tp|p=32401215|t=2020. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study.|pdf=|usr=008}}
+
 
+
{{tp|p=32410266|t=2020. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.|pdf=|usr=008}}
+
{{tp|p=32410234|t=2020. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.|pdf=|usr=008}}
+
 
+
{{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32474026|t=2020. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?|pdf=|usr=008}}
+
{{tp|p=32422320|t=2020. p38 MAPK inhibition: A promising therapeutic approach for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32454981|t=2020. Current regulatory approaches for accessing potential COVID-19 therapies.|pdf=|usr=008}}
+
{{tp|p=32468385|t=2020. Musings on the current state of COVID-19 modeling and reporting.|pdf=|usr=008}}
+
{{tp|p=32435882|t=2020. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2.|pdf=|usr=008}}
+
 
+
{{tp|p=32406687|t=2020. In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.|pdf=|usr=008}}
+
 
+
{{tp|p=32452670|t=2020. Immunity-Boosting Spices and the Novel Coronavirus.|pdf=|usr=008}}
+
{{tp|p=32525650|t=2020. Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?|pdf=|usr=008}}
+
{{tp|p=32534130|t=2020. EPO in Patients With COVID-19: More Than an Erythropoietic Hormone.|pdf=|usr=008}}
+
 
+
{{tp|p=32432518|t=2020. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.|pdf=|usr=008}}
+
{{tp|p=32525715|t=2020. Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.|pdf=|usr=008}}
+
{{tp|p=32396382|t=2020. Myth Busters: Dietary Supplements and COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523147|t=2020. Anotaciones breves sobre el sindrome de liberacion de citocinas y el bloqueo terapeutico de la interleucina-6 en SARS-CoV-2/COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523144|t=2020. Protocolo para la prevencion de arritmias ventriculares debido al tratamiento en pacientes con COVID-19.|pdf=|usr=008}}
+
{{tp|p=32518135|t=2020. Paediatric treatment trials for COVID-19 are an ethical imperative.|pdf=|usr=008}}
+
{{tp|p=32522067|t=2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.|pdf=|usr=008}}
+
{{tp|p=32521191|t=2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?|pdf=|usr=008}}
+
{{tp|p=32515023|t=2020. A call for the appropriate application of clinical pharmacological principles in the search for safe and efficacious COVID-19 (SARS-COV-2) treatments.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32533795|t=2020. Further aspects of doxycycline therapy in COVID-19.|pdf=|usr=008}}
+
{{tp|p=32533990|t=2020. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?|pdf=|usr=008}}
+
{{tp|p=32529218|t=2020. Statin therapy in COVID-19 infection: much more than a single pathway.|pdf=|usr=008}}
+
 
+
{{tp|p=32520031|t=2020. In silico evaluation of marine fish proteins as nutritional supplements for COVID-19 patients.|pdf=|usr=008}}
+
{{tp|p=32516818|t=2020. Interim Management of COVID-19 by Repurposed Homeopathic Medicines.|pdf=|usr=008}}
+
{{ttp|p=32535597|t=2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.|pdf=|usr=008}}
+
{{tp|p=32513070|t=2020. Selenium supplementation can relieve the clinical complications of COVID-19 and other similar viral infections.|pdf=|usr=008}}
+
{{tp|p=32380847|t=2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence.|pdf=|usr=008}}
+
{{tp|p=32516380|t=2020. Covid-19's Impact on Podiatry in Chicago's Largest Public Hospital.|pdf=|usr=008}}
+
{{tp|p=32513665|t=2020. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32515404|t=2020. Comprehensive overview of COVID-19 clinical trials.|pdf=|usr=008}}
+
{{tp|p=32515383|t=2020. Treatment options in people with COVID19: Selecting the best armamentarium against the novel virus.|pdf=|usr=008}}
+
{{tp|p=32521159|t=2020. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.|pdf=|usr=008}}
+
 
+
{{tp|p=32474860|t=2020. Potential of Arbidol for Post-exposure Prophylaxis of COVID-19 Transmission-A Preliminary Report of a Retrospective Cohort Study.|pdf=|usr=008}}
+
{{tp|p=32395418|t=2020. An Update on Current Therapeutic Drugs Treating COVID-19.|pdf=|usr=008}}
+
{{tp|p=32391242|t=2020. A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.|pdf=|usr=008}}
+
{{tp|p=32467020|t=2020. Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment?|pdf=|usr=008}}
+
{{tp|p=32425691|t=2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.|pdf=|usr=008}}
+
{{tp|p=32385829|t=2020. COVID-19 and off label use of drugs: an ethical viewpoint.|pdf=|usr=008}}
+
{{tp|p=32449265|t=2020. Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.|pdf=|usr=008}}
+
 
+
{{tp|p=32418299|t=2020. The COVID-19 chemoprophylactic conundrum: Are we limiting available resources?|pdf=|usr=008}}
+
{{tp|p=32406143|t=2020. Could patients taking isotretinoin therapy be immune against SARS-CoV-2?|pdf=|usr=008}}
+
 
+
{{tp|p=32390307|t=2020. Practical tips for using masks in the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32358890|t=2020. Cutaneous side-effects of the potential COVID-19 drugs.|pdf=|usr=008}}
+
 
+
{{tp|p=32447102|t=2020. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients.|pdf=|usr=008}}
+
 
+
{{tp|p=32428864|t=2020. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.|pdf=|usr=008}}
+
 
+
{{tp|p=32526626|t=2020. Response to 'Vitamin D concentrations and COVID-19 infection in UK Biobank'.|pdf=|usr=008}}
+
{{tp|p=32334392|t=2020. Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.|pdf=|usr=008}}
+
{{tp|p=32335097|t=2020. SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?|pdf=|usr=008}}
+
{{tp|p=32446796|t=2020. Metformin, neutrophils and COVID-19 infection.|pdf=|usr=008}}
+
{{tp|p=32416120|t=2020. Is DPP4 inhibition a comrade or adversary in COVID-19 infection.|pdf=|usr=008}}
+
{{tp|p=32360697|t=2020. Metformin in COVID-19: A possible role beyond diabetes.|pdf=|usr=008}}
+
{{tp|p=32339534|t=2020. COVID-19 and diabetes: Is metformin a friend or foe?|pdf=|usr=008}}
+
{{tp|p=32234504|t=2020. COVID-19, diabetes mellitus and ACE2: The conundrum.|pdf=|usr=008}}
+
{{tp|p=32447736|t=2020. Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.|pdf=|usr=008}}
+
{{tp|p=32514859|t=2020. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.|pdf=|usr=008}}
+
 
+
{{tp|p=32468196|t=2020. Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.|pdf=|usr=008}}
+
{{tp|p=32451923|t=2020. The G-Quadruplex/Helicase World as a Potential Antiviral Approach Against COVID-19.|pdf=|usr=008}}
+
{{tp|p=32523611|t=2020. A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic.|pdf=|usr=008}}
+
{{tp|p=32499832|t=2020. Pharmacological treatment of COVID-19: lights and shadows.|pdf=|usr=008}}
+
{{tp|p=32520599|t=2020. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.|pdf=|usr=008}}
+
 
+
{{tp|p=32469436|t=2020. Physicochemical properties of SARS-CoV-2 for drug targeting, virus inactivation and attenuation, vaccine formulation and quality control.|pdf=|usr=008}}
+
{{tp|p=32378805|t=2020. COVID-19 and toxicity from potential treatments: Panacea or poison.|pdf=|usr=008}}
+
{{tp|p=32475694|t=2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.|pdf=|usr=008}}
+
{{tp|p=32482569|t=2020. Nutricion Clinica en tiempos de COVID-19.|pdf=|usr=008}}
+
{{tp|p=32495654|t=2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.|pdf=|usr=008}}
+
{{tp|p=32379302|t=2020. Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management.|pdf=|usr=008}}
+
{{tp|p=32523930|t=2020. Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome.|pdf=|usr=008}}
+
{{tp|p=32399455|t=2020. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome.|pdf=|usr=008}}
+
 
+
{{tp|p=32518390|t=2020. Editorial: Nutrition and COVID-19.|pdf=|usr=008}}
+
{{tp|p=32433599|t=2020. Nutritional management of COVID-19 patients in a rehabilitation unit.|pdf=|usr=008}}
+
{{tp|p=32404899|t=2020. Clinical significance of nutritional risk screening for older adult patients with COVID-19.|pdf=|usr=008}}
+
{{tp|p=32398871|t=2020. Perspective: improving vitamin D status in the management of COVID-19.|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32482597|t=2020. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.|pdf=|usr=008}}
+
{{tp|p=32448770|t=2020. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.|pdf=|usr=008}}
+
{{tp|p=32425364|t=2020. Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation.|pdf=|usr=008}}
+
{{tp|p=32405160|t=2020. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.|pdf=|usr=008}}
+
{{tp|p=32414641|t=2020. The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed.|pdf=|usr=008}}
+
 
+
{{tp|p=32430428|t=2020. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.|pdf=|usr=008}}
+
{{tp|p=32398309|t=2020. Could the smoking gun in the fight against Covid-19 be the (rh) ACE2?|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32398976|t=2020. siRNA could be a potential therapy for COVID-19.|pdf=|usr=008}}
+
{{tp|p=32518634|t=2020. Lithium and coronaviral infections. A scoping review.|pdf=|usr=008}}
+
{{tp|p=32518636|t=2020. A snapshot of the ongoing clinical research on COVID-19.|pdf=|usr=008}}
+
{{tp|p=32395702|t=2020. The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?|pdf=|usr=008}}
+
 
+
{{tp|p=32426374|t=2020. Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.|pdf=|usr=008}}
+
{{tp|p=32391369|t=2020. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature.|pdf=|usr=008}}
+
{{tp|p=32425923|t=2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?|pdf=|usr=008}}
+
{{tp|p=32390971|t=2020. The Current and Future State of Vaccines, Antivirals and Gene Therapies Against Emerging Coronaviruses.|pdf=|usr=008}}
+
{{tp|p=32468851|t=2020. Facing the SARS-CoV-2 outbreak in the immunotherapy era.|pdf=|usr=008}}
+
{{tp|p=32406749|t=2020. Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients' care.|pdf=|usr=008}}
+
{{tp|p=32406253|t=2020. Bacillus Calmette Guerin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?|pdf=|usr=008}}
+
{{tp|p=32523109|t=2020. Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32535732|t=2020. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32501513|t=2020. How to Rapidly Determine First-in-Children Dosing for COVID-19 Therapeutics.|pdf=|usr=008}}
+
{{tp|p=32433861|t=2020. How to Discover Antiviral Drugs Quickly.|pdf=|usr=008}}
+
{{tp|p=32515974|t=2020. Spiky Nanostructures with Geometry-matching Topography for Virus Inhibition.|pdf=|usr=008}}
+
 
+
{{tp|p=32514101|t=2020. First antibody against COVID-19 spike protein enters phase I.|pdf=|usr=008}}
+
{{tp|p=32516797|t=2020. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.|pdf=|usr=008}}
+
{{tp|p=32529963|t=2020. Can lactoferrin boost human immunity against COVID-19?|pdf=|usr=008}}
+
{{tp|p=32535509|t=2020. COVID-19, interferons, and depression: A commentary.|pdf=|usr=008}}
+
{{tp|p=32409452|t=2020. Pandemic could add noise to clinical trial data.|pdf=|usr=008}}
+
 
+
{{tp|p=32527823|t=2020. Aggregating data from COVID-19 trials.|pdf=|usr=008}}
+
{{tp|p=32527819|t=2020. Can existing live vaccines prevent COVID-19?|pdf=|usr=008}}
+
 
+
{{tp|p=32520641|t=2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.|pdf=|usr=008}}
+
{{tp|p=32520639|t=2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".|pdf=|usr=008}}
+
 
+
{{tp|p=32515337|t=2020. [Remdesivir til behandling af COVID-19-pneumoni].|pdf=|usr=008}}
+
 
+
 
+
{{tp|p=32470338|t=2020. MORTALITY FROM COVID-19 INCREASES WITH UNSATURATED FAT, AND MAY BE REDUCED BY EARLY CALCIUM AND ALBUMIN SUPPLEMENTATION.|pdf=|usr=008}}
+
{{tp|p=32446698|t=2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.|pdf=|usr=008}}
+
{{tp|p=32427166|t=2020. Natural experiment concept to accelerate the Re-purposing of existing therapeutics for Covid-19.|pdf=|usr=008}}
+
{{tp|p=32385749|t=2020. Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.|pdf=|usr=008}}
+
 
+
 
+
 
+
 
+
 
+
 
+
 
+
===007===
+
 
+
 
+
 
+
{{tp|p=32496248|t=2020. Effectiveness of preventive measures against COVID-19: A systematic review of In Silico modeling studies in indian context.|pdf=|usr=007}}
+
{{tp|p=32496246|t=2020. Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32476308|t=2020. Empirical Treatment and Prevention of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32466136|t=2020. Towards Precision Medicine: Inclusion of Sex and Gender Aspects in COVID-19 Clinical Studies-Acting Now before It Is Too Late-A Joint Call for Action.|pdf=|usr=007}}
+
 
+
{{tp|p=32486229|t=2020. Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations.|pdf=|usr=007}}
+
{{tp|p=32481690|t=2020. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases.|pdf=|usr=007}}
+
{{tp|p=32471278|t=2020. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.|pdf=|usr=007}}
+
{{tp|p=32471272|t=2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32443911|t=2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32429572|t=2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.|pdf=|usr=007}}
+
{{tp|p=32429099|t=2020. Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32408699|t=2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.|pdf=|usr=007}}
+
{{tp|p=32392184|t=2020. Clinical trials for COVID-19 should include sex as a variable.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32457038|t=2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.|pdf=|usr=007}}
+
 
+
{{tp|p=32423974|t=2020. COVID-19 and Rheumatology patients on immunomodulatory therapy - can we extrapolate data from previous viral pandemics?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32475104|t=2020. Coronavirus Disease 2019 Presenting as Conjunctivitis.|pdf=|usr=007}}
+
{{tp|p=32293020|t=2020. Palliativ farmakologisk behandling vid svar covid-19.|pdf=|usr=007}}
+
{{tp|p=32444382|t=2020. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=007}}
+
{{tp|p=32442946|t=2020. inverted question markBCG versus COVID-19?|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32162896|t=2020. Possible therapeutic role of a highly standardized mixture of active compounds derived from cultured Lentinula edodes mycelia (AHCC) in patients infected with 2019 novel coronavirus.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32455942|t=2020. Potential Therapeutic Targeting of Coronavirus Spike Glycoprotein Priming.|pdf=|usr=007}}
+
 
+
{{tp|p=32408547|t=2020. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).|pdf=|usr=007}}
+
{{tp|p=32486364|t=2020. Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32486488|t=2020. Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32418757|t=2020. Pancreatic cancer: Does a short course of carbon ion radiotherapy worth during COVID-19 outbreak?|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32423024|t=2020. The Rationale for Potential Pharmacotherapy of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32434254|t=2020. Challenges at the Time of COVID-19: Opportunities and Innovations in Antivirals from Nature.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32505040|t=2020. The end of 'cordon sanitaire' in Wuhan: the role of non-pharmaceutical interventions against COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32381590|t=2020. Ethics of controlled human infection to address COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32472939|t=2020. Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland.|pdf=|usr=007}}
+
 
+
{{tp|p=32395792|t=2020. COVID-19: Main therapeutic options.|pdf=|usr=007}}
+
{{tp|p=32507409|t=2020. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32486283|t=2020. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.|pdf=|usr=007}}
+
{{tp|p=32397643|t=2020. Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA.|pdf=|usr=007}}
+
 
+
{{tp|p=32485102|t=2020. Current Perspective of Antiviral Strategies against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32369098|t=2020. Understanding Observational Treatment Comparisons in the Setting of Coronavirus Disease 2019 (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32398377|t=2020. Reply to Kesici et al. and Zeng et al.: Blocking the virus and reducing the inflammatory damage in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32462848|t=2020. Interleukine-1 et blocage du COVID-19.|pdf=|usr=007}}
+
{{tp|p=32495979|t=2020. Emergence of novel coronavirus and progress toward treatment and vaccine.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32500793|t=2020. Repurposing Nimesulide, a Potent Inhibitor of the B0AT1 Subunit of the SARS-CoV-2 Receptor, as a Therapeutic Adjuvant of COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32433189|t=2020. Important interactions of immunosuppressants with experimental therapies for novel coronavirus disease (COVID-19): how to act.|pdf=|usr=007}}
+
 
+
{{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32391659|t=2020. [Pharmaceutical care for severe and critically ill patients with COVID-19].|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32057209|t=2020. [Pharmacotherapeutics for the New Coronavirus Pneumonia].|pdf=|usr=007}}
+
{{tp|p=32397700|t=2020. [Analysis of application of herd immunity as a control strategy for COVID-19].|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32473600|t=2020. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32491981|t=2020. Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings-International Travel-Related Measures.|pdf=|usr=007}}
+
{{tp|p=32487283|t=2020. Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020.|pdf=|usr=007}}
+
{{tp|p=32490731|t=2020. Targeting SARS-CoV-2 Receptors as a Means for Reducing Infectivity and Improving Antiviral and Immune Response: An Algorithm-based Method For Overcoming Resistance To Antiviral Agents.|pdf=|usr=007}}
+
 
+
{{tp|p=32403995|t=2020. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity.|pdf=|usr=007}}
+
{{tp|p=32499303|t=2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.|pdf=|usr=007}}
+
{{tp|p=32496239|t=2020. Potential pharmacological agents for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32496237|t=2020. AYUSH for COVID-19: Science or Superstition?|pdf=|usr=007}}
+
{{tp|p=32454489|t=2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.|pdf=|usr=007}}
+
{{tp|p=32392562|t=2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32510105|t=2020. COVID-19: A Personalized Cardiometabolic Approach for Reducing Complications and Costs. The Role of Aging beyond Topics.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32505909|t=2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.|pdf=|usr=007}}
+
 
+
{{tp|p=32492560|t=2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?|pdf=|usr=007}}
+
{{tp|p=32460209|t=2020. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.|pdf=|usr=007}}
+
 
+
{{tp|p=32454510|t=2020. Potential Immunoregulatory and Antiviral/SARS-CoV-2 Activities of Nitric Oxide.|pdf=|usr=007}}
+
 
+
{{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32442323|t=2020. Curcumin as a potential treatment for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32430996|t=2020. Potential effects of curcumin in the treatment of COVID-19 infection.|pdf=|usr=007}}
+
 
+
{{tp|p=32503877|t=2020. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32492211|t=2020. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China.|pdf=|usr=007}}
+
 
+
{{tp|p=32492205|t=2020. COVID-19 patients benefit from early antiviral treatment: a comparative, retrospective study.|pdf=|usr=007}}
+
 
+
{{tp|p=32421836|t=2020. Potential pharmacological perspectives for the treatment/prevention of the SARS-COV-2 infection in opioid dependent patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32427774|t=2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.|pdf=|usr=007}}
+
{{tp|p=32427277|t=2020. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.|pdf=|usr=007}}
+
{{tp|p=32495940|t=2020. Probiotics and COVID-19: is there any link?|pdf=|usr=007}}
+
{{tp|p=32504751|t=2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.|pdf=|usr=007}}
+
{{tp|p=32505910|t=2020. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1beta/neutrophil extracellular traps feedback loop.|pdf=|usr=007}}
+
{{tp|p=32502901|t=2020. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis.|pdf=|usr=007}}
+
 
+
{{tp|p=32369285|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369284|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369283|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369282|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32369281|t=2020. A Trial of Lopinavir-Ritonavir in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32438383|t=2020. Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection.|pdf=|usr=007}}
+
{{tp|p=32325475|t=2020. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections.|pdf=|usr=007}}
+
 
+
{{tp|p=32393915|t=2020. Biggest COVID-19 trial tests repurposed drugs first.|pdf=|usr=007}}
+
{{tp|p=32417850|t=2020. Drug researchers pursue new lines of attack against COVID-19.|pdf=|usr=007}}
+
{{tp|p=32415300|t=2020. Biotech companies prepare for COVID-19 downturn.|pdf=|usr=007}}
+
{{tp|p=32415251|t=2020. 15 drugs being tested to treat COVID-19 and how they would work.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32422645|t=2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.|pdf=|usr=007}}
+
{{tp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.|pdf=|usr=007}}
+
{{tp|p=32415276|t=2020. The sprint to solve coronavirus protein structures - and disarm them with drugs.|pdf=|usr=007}}
+
{{tp|p=32409766|t=2020. Dozens of coronavirus drugs are in development - what happens next?|pdf=|usr=007}}
+
{{tp|p=32405023|t=2020. Coronavirus drugs trials must get bigger and more collaborative.|pdf=|usr=007}}
+
 
+
{{tp|p=32512579|t=2020. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe.|pdf=|usr=007}}
+
{{tp|p=32504019|t=2020. The coronavirus outbreak could make it quicker and easier to trial drugs.|pdf=|usr=007}}
+
{{tp|p=32424192|t=2020. CRISPR tool scales up to interrogate a huge line-up of viral suspects.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32324361|t=2020. [Farmakoterapias lehetosegek SARS-CoV-2-fertozes/COVID-19-betegseg eseten]|pdf=|usr=007}}
+
 
+
{{tp|p=32398330|t=2020. A Call for Pediatric COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32423342|t=2020. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?|pdf=|usr=007}}
+
{{tp|p=32393419|t=2020. Recent advances of therapeutic targets and potential drugs of COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32472655|t=2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.|pdf=|usr=007}}
+
{{tp|p=32501634|t=2020. Can Hypericum perforatum (SJW) prevent cytokine storm in COVID-19 patients?|pdf=|usr=007}}
+
{{tp|p=32488956|t=2020. Can concomitant use of zinc and curcumin with other immunity-boosting nutraceuticals be the arsenal against COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32439730|t=2020. Use of specific antimicrobials for COVID-19: should we prescribe them now or wait for more evidence?|pdf=|usr=007}}
+
 
+
{{tp|p=32116200|t=2020. COVID-19: Perspectives on the Potential Novel Global Threat.|pdf=|usr=007}}
+
 
+
{{tp|p=32385052|t=2020. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32381697|t=2020. The race is on for antibodies that stop the new coronavirus.|pdf=|usr=007}}
+
{{tp|p=32381692|t=2020. Combination prevention for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32461212|t=2020. Reducing transmission of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32385101|t=2020. Rapid repurposing of drugs for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32327575|t=2020. NIH organizes hunt for drugs.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32409433|t=2020. Antivirals for COVID-19.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32420637|t=2020. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.|pdf=|usr=007}}
+
{{tp|p=32294756|t=2020. Intervencoes nao farmacologicas para o enfrentamento a epidemia da COVID-19 no Brasil.|pdf=|usr=007}}
+
 
+
{{tp|p=32438473|t=2020. Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.|pdf=|usr=007}}
+
 
+
{{tp|p=32512271|t=2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32448098|t=2020. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.|pdf=|usr=007}}
+
 
+
{{tp|p=32448085|t=2020. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.|pdf=|usr=007}}
+
 
+
{{tp|p=32431217|t=2020. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M(pro)) of SARS-CoV-2 and inhibit its activity.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32469418|t=2020. Evaluation of potential therapeutic options for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32441805|t=2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.|pdf=|usr=007}}
+
{{tp|p=32437001|t=2020. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope".|pdf=|usr=007}}
+
 
+
{{tp|p=32472779|t=2020. Food protein-derived antihypertensive peptides in the COVID-19 pandemic: friends of foes?|pdf=|usr=007}}
+
{{tp|p=32508069|t=2020. Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32470199|t=2020. Metformin use amid coronavirus disease 2019 pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32458502|t=2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32458475|t=2020. Ratcheting down the virulence of SARS-CoV-2 in the COVID-19 pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32458425|t=2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32437019|t=2020. Baricitinib: A chance to treat COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32463459|t=2020. Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States.|pdf=|usr=007}}
+
 
+
{{tp|p=32428941|t=2020. Potential Unconventional Medicines for the Treatment of SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32498081|t=2020. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32449669|t=2020. A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics.|pdf=|usr=007}}
+
 
+
{{tp|p=32495917|t=2020. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
{{tp|p=32427004|t=2020. Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?|pdf=|usr=007}}
+
{{tp|p=32452701|t=2020. An up-to-date overview of computational polypharmacology in modern drug discovery.|pdf=|usr=007}}
+
 
+
{{tp|p=32447996|t=2020. Treatments in the COVID-19 pandemic: an update on clinical trials.|pdf=|usr=007}}
+
{{tp|p=32475183|t=2020. Does lopinavir measure up in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32282262|t=2020. Treatment considerations for coronavirus (COVID-19).|pdf=|usr=007}}
+
{{tp|p=32469280|t=2020. COVID-19: Gene Transfer to the Rescue?|pdf=|usr=007}}
+
{{tp|p=32423245|t=2020. The Impact of the COVID-19 Pandemic on the Biotech Industry.|pdf=|usr=007}}
+
{{tp|p=32212981|t=2020. A Message to Our Community in the Midst of the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32501133|t=2020. Vaccine repurposing approach for preventing COVID 19: can MMR vaccines reduce morbidity and mortality?|pdf=|usr=007}}
+
{{tp|p=32503817|t=2020. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.|pdf=|usr=007}}
+
{{tp|p=32503816|t=2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.|pdf=|usr=007}}
+
 
+
{{tp|p=32503814|t=2020. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32449676|t=2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.|pdf=|usr=007}}
+
{{tp|p=32468014|t=2020. Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic insights into current COVID19 therapies (Review).|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32310670|t=2020. Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32443151|t=2020. Lopinavir pharmacokinetics in COVID-19 patients.|pdf=|usr=007}}
+
{{tp|p=32462858|t=2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.|pdf=|usr=007}}
+
{{tp|p=32469279|t=2020. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32462988|t=2020. A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem).|pdf=|usr=007}}
+
 
+
{{tp|p=32475223|t=2020. Antiviral effects of probiotic metabolites on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32462970|t=2020. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32462996|t=2020. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment.|pdf=|usr=007}}
+
 
+
{{tp|p=32476574|t=2020. Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms.|pdf=|usr=007}}
+
{{tp|p=32485061|t=2020. Incidence and Determinants of QT Interval Prolongation in COVID-19 Patients Treated with Hydroxychloroquine and Azithromycin.|pdf=|usr=007}}
+
 
+
{{tp|p=32433345|t=2020. The pharmacological development of direct acting agents for emerging needed therapy against SARS-CoV-2.|pdf=|usr=007}}
+
 
+
{{tp|p=32473011|t=2020. Potential inhibition of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNFalpha antibodies: a case report.|pdf=|usr=007}}
+
{{tp|p=32504739|t=2020. Interleukin-17: A potential therapeutic target in COVID-19.|pdf=|usr=007}}
+
{{tp|p=32473010|t=2020. TPE-nAbs combination therapy for severe COVID-19.|pdf=|usr=007}}
+
{{tp|p=32220033|t=2020. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).|pdf=|usr=007}}
+
 
+
{{tp|p=32511912|t=2020. COVID-19: Drug targets and potential treatments.|pdf=|usr=007}}
+
{{tp|p=32469301|t=2020. Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2.|pdf=|usr=007}}
+
 
+
{{tp|p=32472703|t=2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients.|pdf=|usr=007}}
+
{{tp|p=32427773|t=2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series.|pdf=|usr=007}}
+
{{tp|p=32364561|t=2020. Randomized Clinical Trials and COVID-19: Managing Expectations.|pdf=|usr=007}}
+
{{tp|p=32463427|t=2020. Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic.|pdf=|usr=007}}
+
{{tp|p=32453363|t=2020. No Benefit for Lopinavir-Ritonavir in Severe COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32506195|t=2020. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32463794|t=2020. Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32434272|t=2020. COVID-19Clinical trials: quality matters more than quantity.|pdf=|usr=007}}
+
 
+
{{tp|p=32464736|t=2020. A simulation training course for family medicine residents in China managing COVID-19.|pdf=|usr=007}}
+
{{tp|p=32505821|t=2020. Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools.|pdf=|usr=007}}
+
 
+
{{tp|p=32455629|t=2020. Tripartite Combination of Candidate Pandemic Mitigation Agents: Vitamin D, Quercetin, and Estradiol Manifest Properties of Medicinal Agents for Targeted Mitigation of the COVID-19 Pandemic Defined by Genomics-Guided Tracing of SARS-CoV-2 Targets in Human Cells.|pdf=|usr=007}}
+
 
+
{{tp|p=32398343|t=2020. Should azithromycin be used to treat COVID-19? A rapid review.|pdf=|usr=007}}
+
 
+
{{tp|p=32454500|t=2020. Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.|pdf=|usr=007}}
+
{{tp|p=32453693|t=2020. Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".|pdf=|usr=007}}
+
{{tp|p=32453692|t=2020. Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32267762|t=2020. Research towards treating COVID-19.|pdf=|usr=007}}
+
 
+
 
+
{{tp|p=32433778|t=2020. Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.|pdf=|usr=007}}
+
{{tp|p=32442317|t=2020. The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).|pdf=|usr=007}}
+
{{tp|p=32441783|t=2020. A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19).|pdf=|usr=007}}
+
{{tp|p=32441764|t=2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?|pdf=|usr=007}}
+
{{tp|p=32424836|t=2020. Lung tissue distribution of drugs as a key factor for COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32449802|t=2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?|pdf=|usr=007}}
+
{{tp|p=32512007|t=2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.|pdf=|usr=007}}
+
{{tp|p=32445484|t=2020. A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.|pdf=|usr=007}}
+
{{tp|p=32438446|t=2020. Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.|pdf=|usr=007}}
+
{{tp|p=32508009|t=2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.|pdf=|usr=007}}
+
{{tp|p=32441462|t=2020. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32511867|t=2020. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID-19 Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32418327|t=2020. Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank.|pdf=|usr=007}}
+
{{ttp|p=32449939|t=2020. SARS-CoV-2 spike glycoprotein-binding proteins expressed by upper respiratory tract bacteria may prevent severe viral infection.|pdf=|usr=007}}
+
 
+
{{tp|p=32420947|t=2020. Stop playing with data: there is no sound evidence that Bacille Calmette-Guerin may avoid SARS-CoV-2 infection (for now).|pdf=|usr=007}}
+
{{tp|p=32420936|t=2020. Treatments for COVID-19: emerging drugs against the coronavirus.|pdf=|usr=007}}
+
{{tp|p=32425152|t=2020. Medicines for the Treatment Of COVID-19: Awaiting the Evidence.|pdf=|usr=007}}
+
{{tp|p=32506621|t=2020. Drugs being investigated for children with COVID-19.|pdf=|usr=007}}
+
 
+
{{tp|p=32423954|t=2020. Accelerating drug development through repurposed FDA approved drugs for COVID-19: speed is important, not haste.|pdf=|usr=007}}
+
 
+
{{tp|p=32493028|t=2020. Letter to the Editor: Repurposing of an Antisepsis Drug in COVID-19 Patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32510142|t=2020. alpha-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32407491|t=2020. iBioProVis: Interactive Visualization and Analysis of Compound Bioactivity Space.|pdf=|usr=007}}
+
 
+
{{tp|p=32403134|t=2020. Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic.|pdf=|usr=007}}
+
{{tp|p=32345591|t=2020. RECOVERY trial: the UK covid-19 study resetting expectations for clinical trials.|pdf=|usr=007}}
+
{{tp|p=32303505|t=2020. Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear.|pdf=|usr=007}}
+
{{tp|p=32407551|t=2020. Interrogation of the safety and efficacy of home-use light-based devices.|pdf=|usr=007}}
+
 
+
{{tp|p=32480418|t=2020. Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of severe COVID-19 patients.|pdf=|usr=007}}
+
 
+
{{tp|p=32498751|t=2020. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps.|pdf=|usr=007}}
+
 
+
{{tp|p=32429705|t=2020. COVID-19 and Nutrition: The Need for Initiatives to Promote Healthy Eating and Prevent Obesity in Childhood.|pdf=|usr=007}}
+
{{tp|p=32412788|t=2020. beta-Arrestin-Biased Angiotensin II Receptor Agonists for COVID-19.|pdf=|usr=007}}
+
{{tp|p=32503806|t=2020. The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.|pdf=|usr=007}}
+
{{tp|p=32474583|t=2020. In Reply: COVID-19: An Argument for Rapid Access to Laboratory Data Warehouses.|pdf=|usr=007}}
+
{{tp|p=32459003|t=2020. A role for retinoids in the treatment of COVID-19?|pdf=|usr=007}}
+
 
+
{{tp|p=32459832|t=2020. Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.|pdf=|usr=007}}
+
{{tp|p=32442287|t=2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells.|pdf=|usr=007}}
+
 
+
 
+
 
+
 
+
 
+
{{tp|p=32498131|t=2020. Pandemic Best Regulatory Practices: An Urgent Need in the Covid-19 Pandemic.|pdf=|usr=007}}
+
 
+
{{tp|p=32350861|t=2020. COVID-19: A Defining Moment for Clinical Pharmacology?|pdf=|usr=007}}
+
{{tp|p=32442315|t=2020. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.|pdf=|usr=007}}
+
 
+
 
+
 
+
{{tp|p=32212378|t=2020. Optimizing COVID-19 Candidate Therapeutics: Thinking Without Borders.|pdf=|usr=007}}
+
 
+
{{tp|p=32284037|t=2020. Perspective on the COVID-19 Coronavirus Outbreak.|pdf=|usr=007}}
+
{{tp|p=32174284|t=2020. A Generic Computer-Assisted Four-Pronged Approach for the Management of Emerging Global Pathogens: Some Comments on COVID-19.|pdf=|usr=007}}
+
{{tp|p=32400323|t=2020. In vitro data of current therapies for SARS-CoV-2.|pdf=|usr=007}}
+
{{tp|p=32427000|t=2020. Implications of the lack of a unified research project framework: an investigation into the registration of clinical trials of COVID-19.|pdf=|usr=007}}
+
  
  
 +
{{tp|p=32628145|t=2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?|pdf=|usr=012}}
 +
{{tp|p=32634024|t=2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32646061|t=2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?|pdf=|usr=012}}
 +
{{tp|p=32638906|t=2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.|pdf=|usr=012}}
 +
{{tp|p=32645994|t=2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.|pdf=|usr=012}}
 +
{{tp|p=32649880|t=2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.|pdf=|usr=012}}
 +
{{tp|p=32641681|t=2020. Is hydroxychloroquine beneficial for COVID-19 patients?|pdf=|usr=012}}
 +
{{tp|p=32638908|t=2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.|pdf=|usr=012}}
 +
{{tp|p=32646869|t=2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.|pdf=|usr=012}}
 +
{{tp|p=32646499|t=2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32631373|t=2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32620147|t=2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.|pdf=|usr=012}}
 +
{{tp|p=32618691|t=2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.|pdf=|usr=012}}
 +
{{tp|p=32640414|t=2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.|pdf=|usr=012}}
 +
{{tp|p=32634717|t=2020. Application of Artificial Intelligence in COVID-19 drug repurposing.|pdf=|usr=012}}
 +
{{tp|p=32639233|t=2020. Concentration-dependent mortality of chloroquine in overdose.|pdf=|usr=012}}
 +
{{tp|p=32619390|t=2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.|pdf=|usr=012}}
 +
{{tp|p=32615862|t=2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.|pdf=|usr=012}}
 +
{{tp|p=32616599|t=2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32640331|t=2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.|pdf=|usr=012}}
 +
{{tp|p=32621202|t=2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.|pdf=|usr=012}}
 +
{{tp|p=32638628|t=2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32622993|t=2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.|pdf=|usr=012}}
 +
{{tp|p=32621881|t=2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).|pdf=|usr=012}}
 +
{{tp|p=32641876|t=2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.|pdf=|usr=012}}
 +
{{tp|p=32641874|t=2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.|pdf=|usr=012}}
 +
{{tp|p=32643111|t=2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.|pdf=|usr=012}}
 +
{{tp|p=32640381|t=2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.|pdf=|usr=012}}
 +
{{tp|p=32642806|t=2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.|pdf=|usr=012}}
 +
{{tp|p=32645633|t=2020. An update on antiviral antibody-based biopharmaceuticals.|pdf=|usr=012}}
 +
{{tp|p=32645632|t=2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32634603|t=2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.|pdf=|usr=012}}
 +
{{tp|p=32646770|t=2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=012}}
 +
{{tp|p=32639711|t=2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.|pdf=|usr=012}}
 +
{{tp|p=32619190|t=2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32648245|t=2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.|pdf=|usr=012}}
 +
{{tp|p=32628223|t=2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.|pdf=|usr=012}}
 +
{{tp|p=32640172|t=2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.|pdf=|usr=012}}
 +
{{tp|p=32634026|t=2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.|pdf=|usr=012}}
 +
{{tp|p=32628535|t=2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.|pdf=|usr=012}}
 +
{{tp|p=32647027|t=2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.|pdf=|usr=012}}
 +
{{tp|p=32632035|t=2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.|pdf=|usr=012}}
 +
{{tp|p=32632034|t=2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.|pdf=|usr=012}}
 +
{{tp|p=32632030|t=2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.|pdf=|usr=012}}
 +
{{tp|p=32620597|t=2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.|pdf=|usr=012}}
 +
{{tp|p=32641296|t=2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.|pdf=|usr=012}}
 +
{{tp|p=32631826|t=2020. Clinical trials of repurposed antivirals for SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32639103|t=2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.|pdf=|usr=012}}
 +
{{tp|p=32644876|t=2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.|pdf=|usr=012}}
 +
{{tp|p=32646867|t=2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.|pdf=|usr=012}}
 +
{{tp|p=32631851|t=2020. Urgent call for greater multilateralism and coordination of covid-19 trials.|pdf=|usr=012}}
 +
{{tp|p=32631850|t=2020. Covid-19: research methods must be flexible in a crisis.|pdf=|usr=012}}
 +
{{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}}
 +
{{tp|p=32611587|t=2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.|pdf=|usr=012}}
 +
{{tp|p=32641344|t=2020. COVID-19 clinical trials: see it big and keep it simple.|pdf=|usr=012}}
 +
{{tp|p=32639062|t=2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32627226|t=2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?|pdf=|usr=012}}
 +
{{tp|p=32645204|t=2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32621754|t=2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.|pdf=|usr=012}}
 +
{{tp|p=32639031|t=2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?|pdf=|usr=012}}
 +
{{tp|p=32640179|t=2020. Current Therapies Under Investigation for COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32633733|t=2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.|pdf=|usr=012}}
 +
{{tp|p=32613971|t=2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.|pdf=|usr=012}}
 +
{{tp|p=32621392|t=2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=012}}
 +
{{tp|p=32640049|t=2020. Immune checkpoint inhibition in the era of COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32640019|t=2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.|pdf=|usr=012}}
 +
{{tp|p=32628748|t=2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.|pdf=|usr=012}}
 +
{{tp|p=32648959|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=012}}
 +
{{tp|p=32634894|t=2020. Smoking in critically ill patients with COVID-19: the Australian experience.|pdf=|usr=012}}
 +
{{tp|p=32628049|t=2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32619167|t=2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.|pdf=|usr=012}}
 +
{{tp|p=32634080|t=2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
 +
{{tp|p=32634079|t=2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.|pdf=|usr=012}}
 +
{{tp|p=32628591|t=2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.|pdf=|usr=012}}
 +
{{tp|p=32648845|t=2020. Therapeutic targets and computational approaches on drug development for COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32621718|t=2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.|pdf=|usr=012}}
 +
{{tp|p=32643448|t=2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32632960|t=2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.|pdf=|usr=012}}
 +
{{tp|p=32629169|t=2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.|pdf=|usr=012}}
 +
{{tp|p=32616659|t=2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32616658|t=2020. BET 1: Lopinavir-ritonavir and COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32641191|t=2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.|pdf=|usr=012}}
 +
{{tp|p=32648935|t=2020. SGLT2 inhibition and COVID-19: The road not taken.|pdf=|usr=012}}
 +
{{tp|p=32620680|t=2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?|pdf=|usr=012}}
 +
{{tp|p=32631083|t=2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32643980|t=2020. Predictor of poor prognosis of COVID-19 patients----liver injury.|pdf=|usr=012}}
 +
{{tp|p=32649840|t=2020. Liver injury in severe COVID-19 infection: current insights and challenges.|pdf=|usr=012}}
 +
{{tp|p=32639083|t=2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.|pdf=|usr=012}}
 +
{{tp|p=32645727|t=2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?|pdf=|usr=012}}
 +
{{tp|p=32643512|t=2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.|pdf=|usr=012}}
 +
{{tp|p=32633162|t=2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.|pdf=|usr=012}}
 +
{{tp|p=32643997|t=2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32615877|t=2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.|pdf=|usr=012}}
 +
{{tp|p=32649272|t=2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?|pdf=|usr=012}}
 +
{{tp|p=32643552|t=2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.|pdf=|usr=012}}
 +
{{tp|p=32643550|t=2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.|pdf=|usr=012}}
 +
{{tp|p=32643529|t=2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.|pdf=|usr=012}}
 +
{{tp|p=32627715|t=2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.|pdf=|usr=012}}
 +
{{tp|p=32627689|t=2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.|pdf=|usr=012}}
 +
{{tp|p=32619162|t=2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.|pdf=|usr=012}}
 +
{{tp|p=32619134|t=2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.|pdf=|usr=012}}
 +
{{tp|p=32618198|t=2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.|pdf=|usr=012}}
 +
{{tp|p=32643158|t=2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.|pdf=|usr=012}}
 +
{{tp|p=32643200|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32647045|t=2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.|pdf=|usr=012}}
 +
{{tp|p=32644254|t=2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.|pdf=|usr=012}}
 +
{{tp|p=32644224|t=2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.|pdf=|usr=012}}
 +
{{tp|p=32644208|t=2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.|pdf=|usr=012}}
 +
{{tp|p=32633865|t=2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.|pdf=|usr=012}}
 +
{{tp|p=32633831|t=2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.|pdf=|usr=012}}
 +
{{tp|p=32621621|t=2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.|pdf=|usr=012}}
 +
{{tp|p=32617989|t=2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=012}}
  
 +
{{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}}
 +
{{tp|p=32629115|t=2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.|pdf=|usr=012}}
 +
{{tp|p=32619764|t=2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.|pdf=|usr=012}}
 +
{{tp|p=32634589|t=2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.|pdf=|usr=012}}
 +
{{tp|p=32623082|t=2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32623080|t=2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.|pdf=|usr=012}}
 +
{{tp|p=32629817|t=2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.|pdf=|usr=012}}
 +
{{tp|p=32617855|t=2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.|pdf=|usr=012}}
 +
{{tp|p=32627127|t=2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.|pdf=|usr=012}}
 +
{{tp|p=32623068|t=2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.|pdf=|usr=012}}
 +
{{tp|p=32634126|t=2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.|pdf=|usr=012}}
 +
{{tp|p=32629768|t=2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.|pdf=|usr=012}}
 +
{{tp|p=32630746|t=2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.|pdf=|usr=012}}
 +
{{tp|p=32622963|t=2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().|pdf=|usr=012}}
 +
{{tp|p=32622008|t=2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.|pdf=|usr=012}}
 +
{{tp|p=32636240|t=2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.|pdf=|usr=012}}
 +
{{tp|p=32611687|t=2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32627442|t=2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.|pdf=|usr=012}}
 +
{{tp|p=32638109|t=2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?|pdf=|usr=012}}
 +
{{tp|p=32646487|t=2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.|pdf=|usr=012}}
 +
{{tp|p=32635935|t=2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.|pdf=|usr=012}}
 +
{{tp|p=32631442|t=2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
 +
{{tp|p=32650019|t=2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32629788|t=2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.|pdf=|usr=012}}
 +
{{tp|p=32610445|t=2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).|pdf=|usr=012}}
 +
{{tp|p=32634550|t=2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.|pdf=|usr=012}}
 +
{{tp|p=32641037|t=2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.|pdf=|usr=012}}
 +
{{tp|p=32647131|t=2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.|pdf=|usr=012}}
 +
{{tp|p=32648153|t=2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.|pdf=|usr=012}}
 +
{{tp|p=32641560|t=2020. COVID-19 and vitamin D deficiency, a fatal combination?|pdf=|usr=012}}
 +
{{tp|p=32645974|t=2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.|pdf=|usr=012}}
 +
{{tp|p=32619723|t=2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?|pdf=|usr=012}}
 +
{{tp|p=32622723|t=2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.|pdf=|usr=012}}
 +
{{tp|p=32629137|t=2020. Ultraviolet-based Biophotonic Technologies and COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32641511|t=2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.|pdf=|usr=012}}
 +
{{tp|p=32621829|t=2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".|pdf=|usr=012}}
 +
{{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=012}}
 +
{{tp|p=32616763|t=2020. A candidate multi-epitope vaccine against SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32638647|t=2020. Alternative management of Covid-19 infection.|pdf=|usr=012}}
 +
{{tp|p=32636116|t=2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.|pdf=|usr=012}}
 +
{{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.|pdf=|usr=012}}
 +
{{tp|p=32629139|t=2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=012}}
 +
{{tp|p=32635353|t=2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.|pdf=|usr=012}}
 +
{{tp|p=32640619|t=2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.|pdf=|usr=012}}
 +
{{tp|p=32635180|t=2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.|pdf=|usr=012}}
 +
{{tp|p=32621841|t=2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32629804|t=2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.|pdf=|usr=012}}
 +
{{tp|p=32620700|t=2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.|pdf=|usr=012}}
 +
{{tp|p=32623965|t=2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?|pdf=|usr=012}}
 +
{{tp|p=32628262|t=2020. The Development of COVID-19 Vaccines: Safeguards Needed.|pdf=|usr=012}}
 +
{{tp|p=32628244|t=2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.|pdf=|usr=012}}
 +
{{tp|p=32614442|t=2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32613691|t=2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.|pdf=|usr=012}}
 +
{{tp|p=32613660|t=2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.|pdf=|usr=012}}
 +
{{tp|p=32619276|t=2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?|pdf=|usr=012}}
 +
{{tp|p=32619669|t=2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.|pdf=|usr=012}}
 +
{{tp|p=32633860|t=2020. Safety of Plasma Infusions in Parkinson's Disease.|pdf=|usr=012}}
 +
{{tp|p=32649078|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.|pdf=|usr=012}}
 +
{{tp|p=32649077|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 +
{{tp|p=32649076|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 +
{{tp|p=32649075|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 +
{{tp|p=32649074|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
 +
{{tp|p=32643410|t=2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.|pdf=|usr=012}}
 +
{{tp|p=32636505|t=2020. COVID-19 platform trial delivers.|pdf=|usr=012}}
 +
{{tp|p=32623442|t=2020. Going back in time for an antibody to fight COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32645305|t=2020. Golden Anniversary of the Nicotinic Receptor.|pdf=|usr=012}}
 +
{{tp|p=32618794|t=2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
 +
{{tp|p=32615642|t=2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.|pdf=|usr=012}}
 +
{{tp|p=32613637|t=2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.|pdf=|usr=012}}
 +
{{tp|p=32648294|t=2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.|pdf=|usr=012}}
 +
{{tp|p=32647056|t=2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
 +
{{tp|p=32648313|t=2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=012}}
 +
{{tp|p=32614102|t=2020. Using heat to kill SARS-CoV-2.|pdf=|usr=012}}
 +
{{tp|p=32646977|t=2020. Can interferons stop COVID-19 before it takes hold?|pdf=|usr=012}}
 +
{{tp|p=32649367|t=2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.|pdf=|usr=012}}
 +
{{tp|p=32619318|t=2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.|pdf=|usr=012}}
 +
{{tp|p=32627216|t=2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.|pdf=|usr=012}}
 +
{{tp|p=32639598|t=2020. SARS-CoV2 and immunosuppression: a double-edged sword.|pdf=|usr=012}}
 +
{{tp|p=32629531|t=2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.|pdf=|usr=012}}
 +
{{tp|p=32614684|t=2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.|pdf=|usr=012}}
  
{{tp|p=32416679|t=2020. Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery.|pdf=|usr=007}}
+
{{tp|p=32388537|t=2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).|pdf=|usr=009}}
{{tp|p=32394841|t=2020. COVID-19: An Update on Clinical Trials.|pdf=|usr=007}}
+
{{tp|p=32532959|t=2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.|pdf=|usr=009}}
{{tp|p=32282303|t=2020. Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.|pdf=|usr=007}}
+
{{tp|p=32423553|t=2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.|pdf=|usr=009}}
{{tp|p=32475041|t=2020. Potential role of Anti-IL-17 in COVID-19 treatment.|pdf=|usr=007}}
+
{{tp|p=32531235|t=2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=009}}
{{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}}
+
{{tp|p=32430279|t=2020. Gut microbiota and Covid-19- possible link and implications.|pdf=|usr=009}}
{{tp|p=32510814|t=2020. Omalizumab and COVID19 Treatment: Could It Help?|pdf=|usr=007}}
+
{{tp|p=32416259|t=2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.|pdf=|usr=009}}
{{tp|p=32510734|t=2020. Azithromycin and COVID-19Prompt Early Use at First Signs of this Infection in Adults and Children An Approach Worthy of Consideration.|pdf=|usr=007}}
+
{{tp|p=32558150|t=2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.|pdf=|usr=010}}
{{tp|p=32510719|t=2020. Intramatricial methotrexate for treatment of resistant acrodermatitis continua of Hallopeau: an alterative in Covid-19.|pdf=|usr=007}}
+
{{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}}
{{tp|p=32500633|t=2020. "Thinking outside the box in COVID-19 era"-Application of Modified Aerosol Box in Dermatology.|pdf=|usr=007}}
+
{{tp|p=32546195|t=2020. Micronutrient status of COVID-19 patients: a critical consideration.|pdf=|usr=010}}
{{tp|p=32419517|t=2020. Emerging therapies for COVID-19 pneumonia.|pdf=|usr=007}}
+
{{tp|p=32559343|t=2020. Rationale for targeting Complement in COVID-19.|pdf=|usr=010}}
{{tp|p=32429703|t=2020. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.|pdf=|usr=007}}
+
{{tp|p=32543705|t=2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.|pdf=|usr=010}}
{{tp|p=32419524|t=2020. Old and re-purposed drugs for the treatment of COVID-19.|pdf=|usr=007}}
+
{{tp|p=32592394|t=2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.|pdf=|usr=010}}
{{tp|p=32223349|t=2020. How could artificial intelligence aid in the fight against coronavirus?|pdf=|usr=007}}
+
{{tp|p=32590326|t=2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.|pdf=|usr=010}}
 +
{{tp|p=32562814|t=2020. Statins and other drugs: Facing COVID-19 as a vascular disease.|pdf=|usr=010}}
 +
{{tp|p=32424591|t=2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?|pdf=|usr=011}}
 +
{{tp|p=32598884|t=2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.|pdf=|usr=011}}
 +
{{tp|p=32481719|t=2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.|pdf=|usr=011}}
 +
{{tp|p=32534506|t=2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?|pdf=|usr=011}}
 +
{{tp|p=32600316|t=2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.|pdf=|usr=011}}
 +
{{tp|p=32537478|t=2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.|pdf=|usr=011}}
 +
{{tp|p=32595361|t=2020. Gut-lung axis and dysbiosis in COVID-19.|pdf=|usr=011}}
 +
{{tp|p=32591496|t=2020. Door to the cell for COVID-19 opened, leading way to therapies.|pdf=|usr=011}}
 +
{{tp|p=32602262|t=2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.|pdf=|usr=011}}
 +
{{tp|p=32555145|t=2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.|pdf=|usr=011}}
 +
{{tp|p=32594085|t=2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.|pdf=|usr=011}}
 +
{{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}}
 +
{{tp|p=32545271|t=2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.|pdf=|usr=011}}
 +
{{ttp|p=32593832|t=2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.|pdf=|usr=011}}
 +
{{tp|p=32573788|t=2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.|pdf=|usr=011}}
 +
{{tp|p=32551652|t=2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=011}}
 +
{{tp|p=32551648|t=2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.|pdf=|usr=011}}
 +
{{tp|p=32571797|t=2020. Identification of common deletions in the spike protein of SARS-CoV-2.|pdf=|usr=011}}
 +
{{tp|p=32606248|t=2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.|pdf=|usr=011}}
 +
{{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}}
  
{{tp|p=32500928|t=2020. COVID-19 breakthroughs: separating fact from fiction.|pdf=|usr=007}}  
+
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
  
 +
{{tp|p=32167678|t=2020. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.|pdf=|usr=013}}
 +
{{tp|p=32405233|t=2020. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.|pdf=|usr=013}}
 +
{{tp|p=32400027|t=2020. Immunological fortification at our barrier organs: Protecting us as we age.|pdf=|usr=013}}
 +
{{tp|p=25762305|t=2015. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32621997|t=2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?|pdf=|usr=013}}
 +
{{tp|p=32621996|t=2020. HCQ induced QT prolongation- Primum non nocere.|pdf=|usr=013}}
 +
{{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32645630|t=2020. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.|pdf=|usr=013}}
 +
{{tp|p=32430515|t=2020. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.|pdf=|usr=013}}
 +
{{tp|p=32654006|t=2020. Emerging pharmacological therapies for ARDS: COVID-19 and beyond.|pdf=|usr=013}}
 +
{{tp|p=32303896|t=2020. Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses.|pdf=|usr=013}}
 +
{{tp|p=32622261|t=2020. Current Status of COVID-19 Therapies and Drug Repositioning Applications.|pdf=|usr=013}}
 +
{{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=013}}
 +
{{tp|p=32339702|t=2020. Role of phototherapy in the era of biologics.|pdf=|usr=013}}
 +
{{tp|p=32622513|t=2020. The roles of PPARgamma and its agonists in autoimmune diseases: A comprehensive review.|pdf=|usr=013}}
 +
{{tp|p=32624376|t=2020. Ayurvedic clinical profile of COVID-19 - A preliminary report.|pdf=|usr=013}}
 +
{{tp|p=32637368|t=2020. COVID-19: Introducing Low Dose Radiation as an Effective Treatment for Pneumonia that Shouldn't Induce Selective Pressure and New Mutations.|pdf=|usr=013}}
 +
{{tp|p=32375574|t=2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32306854|t=2020. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.|pdf=|usr=013}}
 +
{{tp|p=18442051|t=2008. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.|pdf=|usr=013}}
 +
{{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=013}}
 +
{{tp|p=32617428|t=2020. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.|pdf=|usr=013}}
 +
{{tp|p=15693056|t=2005. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.|pdf=|usr=013}}
 +
{{tp|p=32594451|t=2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.|pdf=|usr=013}}
 +
{{tp|p=32535155|t=2020. The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection.|pdf=|usr=013}}
 +
{{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=013}}
 +
{{tp|p=28864360|t=2018. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.|pdf=|usr=013}}
 +
{{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=013}}
 +
{{tp|p=18324609|t=2008. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry.|pdf=|usr=013}}
 +
{{tp|p=32398885|t=2020. How materials can beat a virus.|pdf=|usr=013}}
 +
{{tp|p=32398884|t=2020. Materials Science in the time of Coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32410212|t=2020. Acute kidney injury is associated with the mortality of coronavirus disease 2019.|pdf=|usr=013}}
 +
{{tp|p=32628003|t=2020. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.|pdf=|usr=013}}
 +
{{tp|p=32617527|t=2020. Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV).|pdf=|usr=013}}
 +
{{tp|p=32301512|t=2020. Drug repositioning: a brief overview.|pdf=|usr=013}}
 +
{{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=013}}
 +
{{tp|p=32624302|t=2020. A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure.|pdf=|usr=013}}
 +
{{tp|p=32642277|t=2020. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial.|pdf=|usr=013}}
 +
{{tp|p=32642225|t=2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32576276|t=2020. "Right-to-Try" experimental drugs: an overview.|pdf=|usr=013}}
 +
{{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=013}}
 +
{{tp|p=32188729|t=2020. Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.|pdf=|usr=013}}
 +
{{tp|p=18199635|t=2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.|pdf=|usr=013}}
 +
{{tp|p=32493486|t=2020. Alveolar lipids in pulmonary disease. A review.|pdf=|usr=013}}
 +
{{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=013}}
 +
{{tp|p=32423569|t=2020. Del empirismo a la evidencia cientifica en el tratamiento con antiviricos en los casos graves de infeccion por coronavirus en tiempos de epidemia.|pdf=|usr=013}}
 +
{{tp|p=32599077|t=2020. Coronavirus vaccine-associated lung immunopathology-what is the significance?|pdf=|usr=013}}
 +
{{tp|p=32600307|t=2020. The alpha7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation.|pdf=|usr=013}}
 +
{{tp|p=32579882|t=2020. Preparing for Pandemics: RNA Vaccines at the Forefront.|pdf=|usr=013}}
 +
{{tp|p=32516954|t=2020. Antiviral Effects of Plant-Derived Essential Oils and Their Components: An Updated Review.|pdf=|usr=013}}
 +
{{tp|p=32325742|t=2020. Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related Respiratory Tract Infections in the Spotlight.|pdf=|usr=013}}
 +
{{tp|p=32295300|t=2020. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.|pdf=|usr=013}}
 +
{{tp|p=32459913|t=2020. Remdesivir - An Important First Step.|pdf=|usr=013}}
 +
{{tp|p=32636478|t=2020. Dexamethasone to the rescue.|pdf=|usr=013}}
 +
{{tp|p=32409740|t=2020. Type I and type III interferon in opposition?|pdf=|usr=013}}
 +
{{tp|p=32378128|t=2020. Drug repurposing in cardiology.|pdf=|usr=013}}
 +
{{tp|p=32651844|t=2020. The 'president's drug'.|pdf=|usr=013}}
 +
{{tp|p=32643072|t=2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.|pdf=|usr=013}}
 +
{{tp|p=32474177|t=2020. Nicotinic acetylcholine receptors regulate clustering, fusion and acidification of the rat brain synaptic vesicles.|pdf=|usr=013}}
 +
{{tp|p=32529044|t=2020. Better patient identification could help fight the coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=013}}
 +
{{tp|p=32579137|t=2020. New international guidance on quality, safety and efficacy of DNA vaccines.|pdf=|usr=013}}
 +
{{tp|p=32579135|t=2020. WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019.|pdf=|usr=013}}
 +
{{tp|p=32536809|t=2020. Is a vitamin D fortification strategy needed?|pdf=|usr=013}}
 +
{{tp|p=32349265|t=2020. Vitamin D and Immunity in Infants and Children.|pdf=|usr=013}}
 +
{{tp|p=32344708|t=2020. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.|pdf=|usr=013}}
 +
{{tp|p=32325790|t=2020. Key Vitamin D Target Genes with Functions in the Immune System.|pdf=|usr=013}}
 +
{{tp|p=32325778|t=2020. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations.|pdf=|usr=013}}
 +
{{tp|p=32290296|t=2020. The Role of Selenium in Health and Disease: Emerging and Recurring Trends.|pdf=|usr=013}}
 +
{{tp|p=32617169|t=2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.|pdf=|usr=013}}
 +
{{tp|p=32551127|t=2020. Covering coronavirus-emerging tools for the fight against the common enemy.|pdf=|usr=013}}
 +
{{tp|p=32653463|t=2020. Vaccines for COVID-19: The current state of play.|pdf=|usr=013}}
 +
{{tp|p=32630514|t=2020. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.|pdf=|usr=013}}
 +
{{tp|p=32590098|t=2020. Global research on artemisinin and its derivatives: Perspectives from patents.|pdf=|usr=013}}
 +
{{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=013}}
 +
{{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=013}}
 +
{{tp|p=32384116|t=2020. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32350142|t=2020. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.|pdf=|usr=013}}
 +
{{tp|p=17567736|t=2007. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine.|pdf=|usr=013}}
 +
{{tp|p=17340634|t=2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.|pdf=|usr=013}}
 +
{{tp|p=32540609|t=2020. Possible beneficial role of throat gargling in the coronavirus disease pandemic.|pdf=|usr=013}}
 +
{{tp|p=32653040|t=2020. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32616298|t=2020. Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=013}}
 +
{{tp|p=32636066|t=2020. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal.|pdf=|usr=013}}
 +
{{tp|p=32593625|t=2020. Melatonin, coronavirus, cardiovascular disease, and the geriatric emergency: let's use everything we have!|pdf=|usr=013}}
 +
{{tp|p=32622732|t=2020. The presence of heart disease worsens prognosis in patients with COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32550880|t=2020. Recommandations EMA sur l'usage compassionnel du remdesivir.|pdf=|usr=013}}
 +
{{tp|p=32537031|t=2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.|pdf=|usr=013}}
 +
{{tp|p=32577525|t=2020. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.|pdf=|usr=013}}
 +
{{tp|p=32179788|t=2020. Ginkgolic acid inhibits fusion of enveloped viruses.|pdf=|usr=013}}
 +
{{tp|p=32448377|t=2020. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.|pdf=|usr=013}}
 +
{{tp|p=32318958|t=2020. How to "Detronize" Virus in Crown - Questions to Current Stem Cell Therapies.|pdf=|usr=013}}
 +
{{tp|p=32537523|t=2020. An aurora of natural products-based drug discovery is coming.|pdf=|usr=013}}
 +
{{tp|p=32612804|t=2020. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.|pdf=|usr=013}}
 +
{{tp|p=32641977|t=2020. Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=013}}
 +
{{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=013}}
 +
{{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=013}}
 +
{{tp|p=32636114|t=2020. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.|pdf=|usr=013}}
 +
{{tp|p=32565057|t=2020. The true historical origin of convalescent plasma therapy.|pdf=|usr=013}}
 +
{{tp|p=32542716|t=2020. Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products.|pdf=|usr=013}}
 +
{{tp|p=32333396|t=2020. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.|pdf=|usr=013}}
 +
{{tp|p=32533558|t=2020. Convalescent plasma - this is no time for competition.|pdf=|usr=013}}
 +
{{tp|p=24117799|t=2014. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.|pdf=|usr=013}}
 +
{{tp|p=32504825|t=2020. Innovative highlights of clinical drug trial design.|pdf=|usr=013}}
 +
{{tp|p=32593869|t=2020. Traditional Chinese Herbal Medication for corona-virus 2019.|pdf=|usr=013}}
 +
{{tp|p=32340868|t=2020. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?|pdf=|usr=013}}
 +
{{tp|p=32651113|t=2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.|pdf=|usr=013}}
 +
{{tp|p=32313527|t=2020. Vacunas contra el coronavirus.|pdf=|usr=013}}
 +
{{tp|p=32395638|t=2020. Chloroquine/Hydroxychloroquine Overdose.|pdf=|usr=013}}
 +
{{tp|p=32240549|t=2020. Pivotal role of convalescent plasma in managing emerging infectious diseases.|pdf=|usr=013}}
 +
{{tp|p=12800213|t=2003. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.|pdf=|usr=013}}
  
{{tp|p=32419212|t=2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?|pdf=|usr=007}}
+
{{tp|p=32596616|t=2020. Extraction, Characterization, and Anticoagulant Activity of a Sulfated Polysaccharide from Bursatella leachii Viscera.|pdf=|usr=013}}
 +
{{tp|p=32579890|t=2020. Targeting drug delivery in the vascular system: Focus on endothelium.|pdf=|usr=013}}
 +
{{tp|p=32654004|t=2020. Comments on: The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.|pdf=|usr=013}}
 +
{{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=013}}
 +
{{tp|p=32624192|t=2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32502485|t=2020. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.|pdf=|usr=013}}
 +
{{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=013}}
 +
{{tp|p=32606531|t=2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?|pdf=|usr=013}}
 +
{{tp|p=32637086|t=2020. A severe refractory COVID-19 patient responding to convalescent plasma; A case series.|pdf=|usr=013}}
 +
{{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=013}}
 +
{{tp|p=32653452|t=2020. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.|pdf=|usr=013}}
 +
{{tp|p=32607398|t=2020. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol.|pdf=|usr=013}}
 +
{{tp|p=32600868|t=2020. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?|pdf=|usr=013}}
 +
{{tp|p=32611537|t=2020. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.|pdf=|usr=013}}
 +
{{tp|p=32603888|t=2020. Clinical implications of nicotine as an antimicrobial agent and immune modulator.|pdf=|usr=013}}
 +
{{tp|p=32626733|t=2020. Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice.|pdf=|usr=013}}
 +
{{tp|p=32443566|t=2020. Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.|pdf=|usr=013}}
 +
{{tp|p=32120929|t=2020. Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.|pdf=|usr=013}}
 +
{{tp|p=32629280|t=2020. COVID19 inhibitors: A prospective therapeutics.|pdf=|usr=013}}
 +
{{tp|p=22446091|t=2012. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.|pdf=|usr=013}}
 +
{{tp|p=32297972|t=2020. Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.|pdf=|usr=013}}
 +
{{tp|p=30597533|t=2019. Synthetic biology for bioengineering virus-like particle vaccines.|pdf=|usr=013}}
 +
{{tp|p=26212697|t=2015. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.|pdf=|usr=013}}
 +
{{tp|p=20809484|t=2010. Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development.|pdf=|usr=013}}
 +
{{tp|p=16321039|t=2005. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.|pdf=|usr=013}}
 +
{{tp|p=32493296|t=2020. Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia.|pdf=|usr=013}}
 +
{{tp|p=32601089|t=2020. Food is medicine: actions to integrate food and nutrition into healthcare.|pdf=|usr=013}}
 +
{{tp|p=32444705|t=2020. Hydrogen peroxide mouthwash.|pdf=|usr=013}}
 +
{{tp|p=32591697|t=2020. New video will promote silver diamine fluoride to children.|pdf=|usr=013}}
 +
{{tp|p=32591690|t=2020. Chlorhexidine has an antiviral effect against viruses.|pdf=|usr=013}}
 +
{{tp|p=32591675|t=2020. Virucidal activity.|pdf=|usr=013}}
 +
{{tp|p=32591671|t=2020. Povidone iodine gargle and mouthwash.|pdf=|usr=013}}
 +
{{tp|p=32307721|t=2020. Extensive hard palate hyperpigmentation associated with chloroquine use.|pdf=|usr=013}}
 +
{{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=013}}
 +
{{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=013}}
 +
{{tp|p=32643603|t=2020. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.|pdf=|usr=013}}
 +
{{tp|p=32442424|t=2020. Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.|pdf=|usr=013}}
 +
{{tp|p=32544459|t=2020. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment.|pdf=|usr=013}}
 +
{{tp|p=32402267|t=2020. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.|pdf=|usr=013}}
 +
{{tp|p=32612152|t=2020. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32629149|t=2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.|pdf=|usr=013}}
 +
{{tp|p=16511823|t=2006. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141.|pdf=|usr=013}}
 +
{{tp|p=23788528|t=2013. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.|pdf=|usr=013}}
 +
{{tp|p=32533956|t=2020. Impact of Small-N Studies During a Pandemic.|pdf=|usr=013}}
 +
{{tp|p=32505301|t=2020. Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice.|pdf=|usr=013}}
 +
{{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=013}}
 +
{{tp|p=32405143|t=2020. Remdesivir - A giant step, or a tiptoe?|pdf=|usr=013}}
 +
{{tp|p=32512231|t=2020. Tuberculosis sepsis after tocilizumab treatment.|pdf=|usr=013}}
 +
{{tp|p=32651020|t=2020. COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.|pdf=|usr=013}}
 +
{{tp|p=32613089|t=2020. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.|pdf=|usr=013}}
 +
{{tp|p=32402130|t=2020. What Do We Know About Remdesivir Drug Interactions?|pdf=|usr=013}}
 +
{{tp|p=32623357|t=2020. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=013}}
 +
{{tp|p=32661494|t=2020. Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.|pdf=|usr=013}}
 +
{{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=013}}
 +
{{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=013}}
 +
{{tp|p=32426753|t=2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.|pdf=|usr=013}}
 +
{{tp|p=32637266|t=2020. Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients.|pdf=|usr=013}}
 +
{{tp|p=32626630|t=2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.|pdf=|usr=013}}
 +
{{tp|p=32637278|t=2020. Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case Report.|pdf=|usr=013}}
 +
{{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=013}}
 +
{{tp|p=32615514|t=2020. Docking approaches for modeling multi-molecular assemblies.|pdf=|usr=013}}
 +
{{tp|p=32399388|t=2020. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.|pdf=|usr=013}}
 +
{{tp|p=32616467|t=2020. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy.|pdf=|usr=013}}
 +
{{tp|p=32616381|t=2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32636055|t=2020. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32227604|t=2020. Repurposing therapeutic agents and herbal medicines to defeat viral nemesis.|pdf=|usr=013}}
 +
{{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=013}}
 +
{{tp|p=32636919|t=2020. Can vitamins and/or supplements provide hope against coronavirus?|pdf=|usr=013}}
 +
{{tp|p=32427191|t=2019. Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.|pdf=|usr=013}}
 +
{{tp|p=32619884|t=2020. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?|pdf=|usr=013}}
 +
{{tp|p=32506216|t=2020. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase(R).|pdf=|usr=013}}
 +
{{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=013}}
 +
{{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=013}}
 +
{{tp|p=32652408|t=2020. Natural and nature-inspired stilbenoids as antiviral agents.|pdf=|usr=013}}
 +
{{tp|p=32616594|t=2020. Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon lambda In Vitro And In Mice.|pdf=|usr=013}}
 +
{{tp|p=32591664|t=2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?|pdf=|usr=013}}
 +
{{tp|p=32587388|t=2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.|pdf=|usr=013}}
 +
{{tp|p=32427967|t=2020. Hydroxychloroquine hitting the headlines-retinal considerations.|pdf=|usr=013}}
 +
{{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32655584|t=2020. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.|pdf=|usr=013}}
 +
{{tp|p=32655583|t=2020. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?|pdf=|usr=013}}
 +
{{tp|p=32655582|t=2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32655581|t=2020. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.|pdf=|usr=013}}
 +
{{tp|p=32655578|t=2020. Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?|pdf=|usr=013}}
 +
{{tp|p=32655577|t=2020. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.|pdf=|usr=013}}
 +
{{tp|p=32636851|t=2020. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).|pdf=|usr=013}}
 +
{{tp|p=32612616|t=2020. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.|pdf=|usr=013}}
 +
{{tp|p=32612613|t=2020. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.|pdf=|usr=013}}
 +
{{tp|p=32582186|t=2020. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.|pdf=|usr=013}}
 +
{{tp|p=32174911|t=2020. Quantitative Proteomic Analysis Reveals Antiviral and Anti-inflammatory Effects of Puerarin in Piglets Infected With Porcine Epidemic Diarrhea Virus.|pdf=|usr=013}}
 +
{{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=013}}
 +
{{tp|p=32655532|t=2020. Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses.|pdf=|usr=013}}
 +
{{tp|p=32636755|t=2020. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32636754|t=2020. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.|pdf=|usr=013}}
 +
{{tp|p=32390855|t=2020. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare.|pdf=|usr=013}}
 +
{{tp|p=32636763|t=2020. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease.|pdf=|usr=013}}
 +
{{tp|p=32636762|t=2020. Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection.|pdf=|usr=013}}
 +
{{tp|p=32352313|t=2020. Incipient need of targeting airway remodeling using advanced drug delivery in chronic respiratory diseases.|pdf=|usr=013}}
 +
{{tp|p=32647807|t=2020. The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.|pdf=|usr=013}}
 +
{{tp|p=32606420|t=2020. The value of targeting recombination as a strategy against coronavirus diseases.|pdf=|usr=013}}
  
{{tp|p=32401673|t=2020. Urgent reconsideration of lung edema as a preventable outcome in COVID-19: inhibition of TRPV4 represents a promising and feasible approach.|pdf=|usr=007}}
 
  
{{tp|p=32428965|t=2020. Exclusion of Pregnant Women from Clinical Trials during the Coronavirus Disease 2019 Pandemic: A Review of International Registries.|pdf=|usr=007}}
+
{{tp|p=32665809|t=2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.|pdf=|usr=014}}
{{tp|p=32479158|t=2020. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?|pdf=|usr=007}}
+
{{tp|p=32665808|t=2020. Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.|pdf=|usr=014}}
{{tp|p=32464083|t=2020. P-selectin blockade in COVID-19-related ARDS.|pdf=|usr=007}}
+
{{tp|p=32667191|t=2020. Hard Nanomaterials in Time of Viral Pandemics.|pdf=|usr=014}}
{{tp|p=32437628|t=2020. COVID-19, Asthma, and Inhaled Corticosteroids (ICS): Another Beneficial Effect of ICS?|pdf=|usr=007}}
+
{{tp|p=32717094|t=2020. Cannabis terapeutico y COVID-19: entre el oportunismo y la infoxicacion.|pdf=|usr=014}}
 +
{{tp|p=32711735|t=2020. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.|pdf=|usr=014}}
 +
{{tp|p=32705585|t=2020. Associations between hypovitaminosis D and COVID-19: a narrative review.|pdf=|usr=014}}
 +
{{tp|p=32653224|t=2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?|pdf=|usr=014}}
 +
{{tp|p=32687406|t=2020. Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe Acute Respiratory Syndrome Coronavirus-2 Infection.|pdf=|usr=014}}
 +
{{tp|p=32653550|t=2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?|pdf=|usr=014}}
 +
{{tp|p=32673060|t=2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.|pdf=|usr=014}}
 +
{{tp|p=32673059|t=2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.|pdf=|usr=014}}
 +
{{tp|p=32667853|t=2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32653425|t=2020. Does androgen deprivation therapy protect against severe complications from COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32692238|t=2020. Tongue diagnosis and treatment in traditional Chinese medicine for severe COVID-19: a case report.|pdf=|usr=014}}
 +
{{tp|p=32660993|t=2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.|pdf=|usr=014}}
 +
{{tp|p=32708578|t=2020. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32679055|t=2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32659293|t=2020. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.|pdf=|usr=014}}
 +
{{tp|p=32659292|t=2020. Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.|pdf=|usr=014}}
 +
{{tp|p=32660794|t=2020. Response to: Amantadine Treatment for People with COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32682671|t=2020. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.|pdf=|usr=014}}
 +
{{tp|p=32710969|t=2020. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32688139|t=2020. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.|pdf=|usr=014}}
 +
{{tp|p=32679775|t=2020. Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target.|pdf=|usr=014}}
 +
{{tp|p=32665234|t=2020. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.|pdf=|usr=014}}
 +
{{tp|p=32717399|t=2020. Purinergic signaling in infectious diseases of the central nervous system.|pdf=|usr=014}}
 +
{{tp|p=32679175|t=2020. Regional differences in use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32679174|t=2020. Reply to the Letter to the Editor: Regional differences in dietary use of immune-modulating catechins should be investigated regarding COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32615072|t=2020. Ivermectin: potential candidate for the treatment of Covid 19.|pdf=|usr=014}}
 +
{{tp|p=32717278|t=2020. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.|pdf=|usr=014}}
 +
{{tp|p=32643141|t=2020. Ion channel inhibition against COVID-19: A novel target for clinical investigation.|pdf=|usr=014}}
 +
{{tp|p=32645327|t=2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.|pdf=|usr=014}}
 +
{{tp|p=32714563|t=2020. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro.|pdf=|usr=014}}
 +
{{tp|p=32707096|t=2020. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.|pdf=|usr=014}}
 +
{{tp|p=32668216|t=2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.|pdf=|usr=014}}
 +
{{tp|p=32711111|t=2020. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32710890|t=2020. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.|pdf=|usr=014}}
 +
{{tp|p=32676976|t=2020. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.|pdf=|usr=014}}
 +
{{tp|p=32632717|t=2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.|pdf=|usr=014}}
 +
{{tp|p=32665783|t=2020. Current strategies against COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32667534|t=2020. Pandemia de COVID19: implicacoes para (in)seguranca alimentar e nutricional.|pdf=|usr=014}}
 +
{{tp|p=32661912|t=2020. Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32661911|t=2020. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32707089|t=2020. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.|pdf=|usr=014}}
 +
{{tp|p=32673711|t=2020. mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.|pdf=|usr=014}}
 +
{{tp|p=32663514|t=2020. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'.|pdf=|usr=014}}
 +
{{tp|p=32675166|t=2020. COVID-19, hydroxychloroquine and the eighth alternative.|pdf=|usr=014}}
 +
{{tp|p=32717568|t=2020. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.|pdf=|usr=014}}
 +
{{tp|p=32705604|t=2020. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?|pdf=|usr=014}}
 +
{{tp|p=32709544|t=2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.|pdf=|usr=014}}
 +
{{tp|p=32668460|t=2020. COVID-19 Therapeutics: Making Sense of It All.|pdf=|usr=014}}
 +
{{tp|p=32662982|t=2020. Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection.|pdf=|usr=014}}
 +
{{tp|p=32687696|t=2020. Old drugs for a new virus: repurposed approaches for combating COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32686128|t=2020. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.|pdf=|usr=014}}
 +
{{tp|p=32696443|t=2020. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.|pdf=|usr=014}}
 +
{{tp|p=32716768|t=2020. The Regulation of COVID-19 "Challenge" Studies.|pdf=|usr=014}}
 +
{{tp|p=32709838|t=2020. Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C.|pdf=|usr=014}}
 +
{{tp|p=32661220|t=2020. First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.|pdf=|usr=014}}
 +
{{tp|p=32694294|t=2020. Nutrition Support in the ICU-A Refresher in the Era of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32668178|t=2020. Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32668164|t=2020. Reply to: Inhaled Corticosteroids and COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32711585|t=2020. More Studies are Needed on the Link between Metformin and Decreased Mortality in Diabetic COVID-19 Patients.|pdf=|usr=014}}
 +
{{tp|p=32705976|t=2020. Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials.|pdf=|usr=014}}
 +
{{tp|p=32663348|t=2020. Current status of COVID-19 (pre)clinical vaccine development.|pdf=|usr=014}}
 +
{{tp|p=32692580|t=2020. Repurposing Existing Drugs for the Treatment of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32687756|t=2020. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.|pdf=|usr=014}}
 +
{{tp|p=32661006|t=2020. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.|pdf=|usr=014}}
 +
{{tp|p=32686943|t=2020. Potential role of Bacillus Calmette-Guerin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.|pdf=|usr=014}}
 +
{{tp|p=32713288|t=2020. Chloroquine in fighting COVID-19: good, bad, or both?|pdf=|usr=014}}
 +
{{tp|p=32692801|t=2020. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32663708|t=2020. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.|pdf=|usr=014}}
 +
{{tp|p=32699011|t=2020. Intensive immunosuppression reduces deaths in covid-19-associated cytokine storm syndrome, study finds.|pdf=|usr=014}}
 +
{{tp|p=32698999|t=2020. Are we responsible for the racial inequalities of covid-19?|pdf=|usr=014}}
 +
{{tp|p=32665225|t=2020. Covid-19: Experts criticise claim that remdesivir cuts death rates.|pdf=|usr=014}}
 +
{{tp|p=32693436|t=2020. Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32692462|t=2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32687645|t=2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.|pdf=|usr=014}}
 +
{{tp|p=32656822|t=2020. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.|pdf=|usr=014}}
 +
{{tp|p=32652563|t=2020. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.|pdf=|usr=014}}
 +
{{tp|p=32713358|t=2020. COVID-19 and Misinformation: How an Infodemic Fueled the prominence of Vitamin D.|pdf=|usr=014}}
 +
{{tp|p=32703328|t=2020. THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.|pdf=|usr=014}}
 +
{{tp|p=32700336|t=2020. Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32681537|t=2020. Safety perspectives on presently considered drugs for the treatment of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32671829|t=2020. Targeting zinc metalloenzymes in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32713374|t=2020. Clozapine treatment and risk of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32662814|t=2020. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.|pdf=|usr=014}}
 +
{{tp|p=32717117|t=2020. Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main Protease of SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32700795|t=2020. Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators.|pdf=|usr=014}}
 +
{{tp|p=32702997|t=2020. IL-6 Blockade and QTc Prolongation in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32671847|t=2020. In response to: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=014}}
 +
{{tp|p=32710937|t=2020. Micronutrients as immunomodulatory tools for COVID-19 management.|pdf=|usr=014}}
 +
{{tp|p=32706859|t=2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.|pdf=|usr=014}}
 +
{{tp|p=32674126|t=2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.|pdf=|usr=014}}
 +
{{tp|p=32671407|t=2020. Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors.|pdf=|usr=014}}
 +
{{tp|p=32667978|t=2020. Treatment of COVID-19 - Evidence-Based or Personalized Medicine?|pdf=|usr=014}}
 +
{{tp|p=32651997|t=2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32687630|t=2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.|pdf=|usr=014}}
 +
{{tp|p=32674594|t=2020. Endpoints for randomized controlled clinical trials for COVID-19 treatments.|pdf=|usr=014}}
 +
{{tp|p=32666816|t=2020. Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.|pdf=|usr=014}}
 +
{{tp|p=32650672|t=2020. Clinical trials in the time of a pandemic.|pdf=|usr=014}}
 +
{{tp|p=32650671|t=2020. Editorial: Clinical trial design in the era of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32651961|t=2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.|pdf=|usr=014}}
 +
{{tp|p=32675717|t=2020. Role for antimalarials in the management of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32674732|t=2020. Ligand- and structure-based virtual screening of Lamiaceae diterpenes with potential activity against a novel coronavirus (2019-nCoV).|pdf=|usr=014}}
 +
{{tp|p=32686260|t=2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32692700|t=2020. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?|pdf=|usr=014}}
 +
{{tp|p=32690491|t=2020. Dexamethasone for COVID-19: preliminary findings.|pdf=|usr=014}}
 +
{{tp|p=32705683|t=2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
 +
{{tp|p=32688337|t=2020. Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.|pdf=|usr=014}}
 +
{{tp|p=32706089|t=2020. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32706087|t=2020. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.|pdf=|usr=014}}
 +
{{tp|p=32700604|t=2020. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.|pdf=|usr=014}}
  
 +
{{tp|p=32658735|t=2020. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.|pdf=|usr=014}}
 +
{{tp|p=32698853|t=2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.|pdf=|usr=014}}
 +
{{tp|p=32693829|t=2020. Chinese herbal experience for the 2019 novel coronavirus.|pdf=|usr=014}}
 +
{{tp|p=32690059|t=2020. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials.|pdf=|usr=014}}
 +
{{tp|p=32684169|t=2020. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study.|pdf=|usr=014}}
 +
{{tp|p=32682440|t=2020. Blocking IL-1 to prevent respiratory failure in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32680535|t=2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.|pdf=|usr=014}}
 +
{{tp|p=32664996|t=2020. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation.|pdf=|usr=014}}
 +
{{tp|p=32653043|t=2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.|pdf=|usr=014}}
 +
{{tp|p=32653015|t=2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.|pdf=|usr=014}}
 +
{{tp|p=32656044|t=2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.|pdf=|usr=014}}
 +
{{tp|p=32661859|t=2020. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?|pdf=|usr=014}}
 +
{{tp|p=32665127|t=2020. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?|pdf=|usr=014}}
 +
{{tp|p=32683320|t=2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).|pdf=|usr=014}}
 +
{{tp|p=32696429|t=2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.|pdf=|usr=014}}
 +
{{tp|p=32696108|t=2020. Pharmaco-Immunomodulatory Therapy in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32655654|t=2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.|pdf=|usr=014}}
 +
{{tp|p=32691021|t=2020. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia.|pdf=|usr=014}}
 +
{{tp|p=32662949|t=2020. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.|pdf=|usr=014}}
 +
{{tp|p=32696234|t=2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.|pdf=|usr=014}}
 +
{{tp|p=32653152|t=2020. Waste in COVID-19 clinical trials conducted in western Europe.|pdf=|usr=014}}
 +
{{tp|p=32651040|t=2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.|pdf=|usr=014}}
 +
{{tp|p=32693294|t=2020. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.|pdf=|usr=014}}
 +
{{tp|p=32668312|t=2020. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.|pdf=|usr=014}}
 +
{{tp|p=32682787|t=2020. Advances in the possible treatment of COVID-19: A review.|pdf=|usr=014}}
 +
{{tp|p=32700671|t=2020. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32707160|t=2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.|pdf=|usr=014}}
 +
{{tp|p=32679367|t=2020. Selenium - associated gene signatures within the SARS-CoV-2 - host genomic interaction interface.|pdf=|usr=014}}
 +
{{tp|p=32653511|t=2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32714335|t=2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.|pdf=|usr=014}}
 +
{{tp|p=32695123|t=2020. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.|pdf=|usr=014}}
 +
{{tp|p=32670297|t=2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.|pdf=|usr=014}}
 +
{{tp|p=32705405|t=2020. Traditional Chinese medicine for combating COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32651936|t=2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.|pdf=|usr=014}}
 +
{{tp|p=32714938|t=2020. Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.|pdf=|usr=014}}
 +
{{tp|p=32671084|t=2020. Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.|pdf=|usr=014}}
 +
{{tp|p=32714193|t=2020. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.|pdf=|usr=014}}
 +
{{tp|p=32698626|t=2020. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.|pdf=|usr=014}}
 +
{{tp|p=32672061|t=2020. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.|pdf=|usr=014}}
 +
{{tp|p=32662664|t=2020. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.|pdf=|usr=014}}
 +
{{tp|p=32682763|t=2020. Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study.|pdf=|usr=014}}
 +
{{tp|p=32717321|t=2020. Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32703797|t=2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.|pdf=|usr=014}}
 +
{{tp|p=32703791|t=2020. Complement C5 inhibition in patients with COVID-19 - a promising target?|pdf=|usr=014}}
 +
{{tp|p=32676695|t=2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.|pdf=|usr=014}}
 +
{{tp|p=32712334|t=2020. Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study.|pdf=|usr=014}}
 +
{{tp|p=32712333|t=2020. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=014}}
 +
{{tp|p=32708322|t=2020. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32717282|t=2020. The Lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32711037|t=2020. Radiation Therapy as a Treatment for COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32707264|t=2020. Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results.|pdf=|usr=014}}
 +
{{tp|p=32713677|t=2020. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.|pdf=|usr=014}}
 +
{{tp|p=32707230|t=2020. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: implications for treatment with IFN-beta and IFN inducer.|pdf=|usr=014}}
 +
{{tp|p=32662677|t=2020. The combination of artificial intelligence and systems biology for intelligent vaccine design.|pdf=|usr=014}}
 +
{{tp|p=32693646|t=2020. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.|pdf=|usr=014}}
 +
{{tp|p=32693650|t=2020. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.|pdf=|usr=014}}
 +
{{tp|p=32693652|t=2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.|pdf=|usr=014}}
 +
{{tp|p=32662690|t=2020. The Use of IV vitamin C for patients with COVID-19: a single center observational study.|pdf=|usr=014}}
 +
{{tp|p=32700398|t=2020. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.|pdf=|usr=014}}
 +
{{tp|p=32657483|t=2020. Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.|pdf=|usr=014}}
 +
{{tp|p=32691927|t=2020. Drug interactions with potential antivirals used for COVID-19 in older persons.|pdf=|usr=014}}
 +
{{tp|p=32701395|t=2020. Designing Pull Funding For A COVID-19 Vaccine.|pdf=|usr=014}}
 +
{{tp|p=32706599|t=2020. A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States.|pdf=|usr=014}}
 +
{{tp|p=32703069|t=2020. Promise and challenges in the development of COVID-19 vaccines.|pdf=|usr=014}}
 +
{{tp|p=32703064|t=2020. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.|pdf=|usr=014}}
 +
{{tp|p=32693665|t=2020. COVID-19 - Important considerations for developing and using a vaccine.|pdf=|usr=014}}
 +
{{tp|p=32663051|t=2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.|pdf=|usr=014}}
 +
{{tp|p=32710535|t=2020. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?|pdf=|usr=014}}
 +
{{tp|p=32713336|t=2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?|pdf=|usr=014}}
 +
{{tp|p=32673140|t=2020. Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?|pdf=|usr=014}}
 +
{{tp|p=32674673|t=2020. COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?|pdf=|usr=014}}
 +
{{tp|p=32666683|t=2020. COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors.|pdf=|usr=014}}
 +
{{tp|p=32673081|t=2020. Chinese Herbal Medicines During the Covid-19 Pandemic: A Role for Observational Studies.|pdf=|usr=014}}
 +
{{tp|p=32659175|t=2020. Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?|pdf=|usr=014}}
 +
{{tp|p=32688374|t=2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.|pdf=|usr=014}}
 +
{{tp|p=32720578|t=2020. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.|pdf=|usr=014}}
 +
{{tp|p=32720577|t=2020. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis.|pdf=|usr=014}}
 +
{{tp|p=32720571|t=2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32715956|t=2020. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32705962|t=2020. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32705953|t=2020. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.|pdf=|usr=014}}
 +
{{tp|p=32705952|t=2020. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M(pro)) from flavonoid based phytochemical constituents of Calendula officinalis.|pdf=|usr=014}}
 +
{{tp|p=32705942|t=2020. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
 +
{{tp|p=32698693|t=2020. Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.|pdf=|usr=014}}
 +
{{tp|p=32698689|t=2020. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.|pdf=|usr=014}}
 +
{{tp|p=32696720|t=2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32696718|t=2020. Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study.|pdf=|usr=014}}
 +
{{tp|p=32692306|t=2020. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.|pdf=|usr=014}}
 +
{{tp|p=32691697|t=2020. Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis.|pdf=|usr=014}}
 +
{{tp|p=32691680|t=2020. Cyanobacterial metabolites as promising drug leads against the M(pro) and PL(pro) of SARS-CoV-2: an in silico analysis.|pdf=|usr=014}}
 +
{{tp|p=32684114|t=2020. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=014}}
 +
{{tp|p=32684109|t=2020. Targeting virus-host interaction by novel pyrimidine derivative: an in silico approach towards discovery of potential drug against COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32679006|t=2020. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)).|pdf=|usr=014}}
 +
{{tp|p=32677591|t=2020. The latitude hypothesis, vitamin D, and SARS-Co-V2.|pdf=|usr=014}}
 +
{{tp|p=32677545|t=2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.|pdf=|usr=014}}
 +
{{tp|p=32677533|t=2020. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.|pdf=|usr=014}}
 +
{{tp|p=32672528|t=2020. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.|pdf=|usr=014}}
 +
{{tp|p=32666910|t=2020. Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.|pdf=|usr=014}}
 +
{{tp|p=32662333|t=2020. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.|pdf=|usr=014}}
 +
{{tp|p=32657643|t=2020. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).|pdf=|usr=014}}
 +
{{tp|p=32697000|t=2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.|pdf=|usr=014}}
 +
{{tp|p=32658005|t=2020. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.|pdf=|usr=014}}
 +
{{tp|p=32700555|t=2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.|pdf=|usr=014}}
 +
{{tp|p=32692858|t=2020. Stem cell therapies for COVID-19: Strategy and application.|pdf=|usr=014}}
 +
{{tp|p=32687345|t=2020. Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease.|pdf=|usr=014}}
 +
{{tp|p=32678588|t=2020. SARS-CoV-2 Main Protease: A Molecular Dynamics Study.|pdf=|usr=014}}
 +
{{tp|p=32694358|t=2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.|pdf=|usr=014}}
 +
{{tp|p=32700580|t=2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.|pdf=|usr=014}}
 +
{{tp|p=32677610|t=2020. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.|pdf=|usr=014}}
 +
{{tp|p=32651218|t=2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.|pdf=|usr=014}}
 +
{{tp|p=32702095|t=2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.|pdf=|usr=014}}
 +
{{tp|p=32651586|t=2020. Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.|pdf=|usr=014}}
  
{{tp|p=32446312|t=2020. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis.|pdf=|usr=007}}
+
{{tp|p=32666357|t=2020. Vitamin D and COVID-19.|pdf=|usr=014}}
{{tp|p=32503855|t=2020. Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.|pdf=|usr=007}}
+
{{tp|p=32685369|t=2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.|pdf=|usr=014}}
 +
{{tp|p=32677493|t=2020. Obesity, COVID-19 and immunotherapy: the complex relationship!|pdf=|usr=014}}
 +
{{tp|p=32664810|t=2020. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.|pdf=|usr=014}}
 +
{{tp|p=32651941|t=2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32656668|t=2020. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.|pdf=|usr=014}}
 +
{{tp|p=32683296|t=2020. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.|pdf=|usr=014}}
 +
{{tp|p=32687949|t=2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.|pdf=|usr=014}}
 +
{{tp|p=32674929|t=2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?|pdf=|usr=014}}
 +
{{tp|p=32674928|t=2020. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.|pdf=|usr=014}}
 +
{{tp|p=32693122|t=2020. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.|pdf=|usr=014}}
 +
{{tp|p=32682041|t=2020. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.|pdf=|usr=014}}
 +
{{tp|p=32698494|t=2020. Self-Amplifying RNA Viruses as RNA Vaccines.|pdf=|usr=014}}
 +
{{tp|p=32674481|t=2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.|pdf=|usr=014}}
 +
{{tp|p=32691002|t=2020. A consensus guideline of herbal medicine for coronavirus disease 2019.|pdf=|usr=014}}
 +
{{tp|p=32691000|t=2020. Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines.|pdf=|usr=014}}
 +
{{tp|p=32652231|t=2020. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.|pdf=|usr=014}}
 +
{{tp|p=32652194|t=2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.|pdf=|usr=014}}
 +
{{tp|p=32674834|t=2020. Plasma Therapies and Parabiosis in the COVID-19 Era.|pdf=|usr=014}}
 +
{{tp|p=32690352|t=2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.|pdf=|usr=014}}
 +
{{tp|p=32694923|t=2020. Blood Targets of Adjuvant Drugs Against COVID19.|pdf=|usr=014}}
 +
{{tp|p=32713161|t=2020. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.|pdf=|usr=014}}
 +
{{tp|p=32677763|t=2020. Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!|pdf=|usr=014}}
 +
{{tp|p=32672454|t=2020. Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.|pdf=|usr=014}}
 +
{{tp|p=32655741|t=2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.|pdf=|usr=014}}
 +
{{tp|p=32683212|t=2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32680687|t=2020. Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.|pdf=|usr=014}}
 +
{{tp|p=32682930|t=2020. Could Bordetella pertussis vaccine protect against coronavirus COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32695833|t=2020. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.|pdf=|usr=014}}
 +
{{tp|p=32652164|t=2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.|pdf=|usr=014}}
 +
{{tp|p=32666875|t=2020. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.|pdf=|usr=014}}
 +
{{tp|p=32654098|t=2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.|pdf=|usr=014}}
 +
{{tp|p=32661074|t=2020. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.|pdf=|usr=014}}
 +
{{tp|p=32702590|t=2020. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.|pdf=|usr=014}}
 +
{{tp|p=32682142|t=2020. Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.|pdf=|usr=014}}
 +
{{tp|p=32684166|t=2020. Withaferin A: a potential therapeutic agent against COVID-19 infection.|pdf=|usr=014}}
 +
{{tp|p=32685234|t=2020. Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32658489|t=2020. Michael Acceptors Tuned by the Pivotal Aromaticity of Histidine to Block COVID-19 Activity.|pdf=|usr=014}}
 +
{{tp|p=32653646|t=2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.|pdf=|usr=014}}
 +
{{tp|p=32718719|t=2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.|pdf=|usr=014}}
 +
{{tp|p=32718715|t=2020. Reacciones adversas a farmacos utilizados en el tratamiento especifico de la infeccion por SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32712223|t=2020. Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action.|pdf=|usr=014}}
 +
{{tp|p=32712272|t=2020. Blood nitrate and nitrite modulating nitric oxide bioavailability: potential therapeutic functions in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32708526|t=2020. Selenium Deficiency Is Associated with Mortality Risk from COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32709055|t=2020. Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance.|pdf=|usr=014}}
 +
{{tp|p=32707768|t=2020. Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the Wished Antiviral Drugs?|pdf=|usr=014}}
 +
{{tp|p=32713784|t=2020. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.|pdf=|usr=014}}
 +
{{tp|p=32703528|t=2020. Replica: Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?|pdf=|usr=014}}
 +
{{tp|p=32719454|t=2020. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates.|pdf=|usr=014}}
 +
{{tp|p=32652766|t=2020. The link between Vitamin D and Covid-19: distinguishing facts from fiction.|pdf=|usr=014}}
 +
{{tp|p=32662708|t=2020. SARS-CoV-2 in the first trimester of pregnancy: potential interference in placentation.|pdf=|usr=014}}
 +
{{tp|p=32692176|t=2020. Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS?|pdf=|usr=014}}
 +
{{tp|p=32716073|t=2020. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients.|pdf=|usr=014}}
 +
{{tp|p=32691896|t=2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.|pdf=|usr=014}}
 +
{{tp|p=32691875|t=2020. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.|pdf=|usr=014}}
 +
{{tp|p=32681650|t=2020. SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.|pdf=|usr=014}}
 +
{{tp|p=32672860|t=2020. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.|pdf=|usr=014}}
 +
{{tp|p=32658304|t=2020. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).|pdf=|usr=014}}
 +
{{tp|p=32651248|t=2020. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.|pdf=|usr=014}}
 +
{{tp|p=32680924|t=2020. Oncology-inspired treatment options for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32710111|t=2020. Vitamin D and COVID-19: Lessons from Spaceflight Analogs.|pdf=|usr=014}}
 +
{{tp|p=32705690|t=2020. Benzothiazoles as potential antiviral agents.|pdf=|usr=014}}
 +
{{tp|p=32650355|t=2020. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.|pdf=|usr=014}}
 +
{{tp|p=32699094|t=2020. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.|pdf=|usr=014}}
 +
{{tp|p=32675436|t=2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.|pdf=|usr=014}}
 +
{{tp|p=32717043|t=2020. Pooling Data From Individual Clinical Trials in the COVID-19 Era.|pdf=|usr=014}}
 +
{{tp|p=32662848|t=2020. COVID-19 Antibody Trials Have Begun.|pdf=|usr=014}}
 +
{{tp|p=32716474|t=2020. Setting Expectations for Clinical Research During the COVID-19 Pandemic.|pdf=|usr=014}}
 +
{{tp|p=32720612|t=2020. [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)].|pdf=|usr=014}}
 +
{{tp|p=32702300|t=2020. Encouraging results from phase 1/2 COVID-19 vaccine trials.|pdf=|usr=014}}
 +
{{tp|p=32702299|t=2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.|pdf=|usr=014}}
 +
{{tp|p=32663575|t=2020. Tackling the cytokine storm in COVID-19, challenges and hopes.|pdf=|usr=014}}
 +
{{tp|p=32720605|t=2020. In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of Novel Coronavirus (COVID-19) and SARS-CoV.|pdf=|usr=014}}
 +
{{tp|p=32679430|t=2020. Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection.|pdf=|usr=014}}
 +
{{tp|p=32678815|t=2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.|pdf=|usr=014}}
 +
{{tp|p=32721082|t=2020. A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32696772|t=2020. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.|pdf=|usr=014}}
 +
{{tp|p=32658332|t=2020. COVID-19 in MuSK Myasthenia Gravis: A Case Report.|pdf=|usr=014}}
 +
{{tp|p=32706953|t=2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32706553|t=2020. Audio Interview: Dexamethasone and Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32678530|t=2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.|pdf=|usr=014}}
 +
{{tp|p=32668131|t=2020. Audio Interview: Covid-19 Vaccine Development.|pdf=|usr=014}}
 +
{{tp|p=32668109|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.|pdf=|usr=014}}
 +
{{tp|p=32668108|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32668107|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32668106|t=2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.|pdf=|usr=014}}
 +
{{tp|p=32669667|t=2020. How computational immunology changed the face of COVID-19 vaccine development.|pdf=|usr=014}}
 +
{{tp|p=32651581|t=2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.|pdf=|usr=014}}
 +
{{tp|p=32669664|t=2020. COVID-19 vaccine development and a potential nanomaterial path forward.|pdf=|usr=014}}
 +
{{tp|p=32699321|t=2020. Controlling the SARS-CoV-2 spike glycoprotein conformation.|pdf=|usr=014}}
 +
{{tp|p=32661423|t=2020. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.|pdf=|usr=014}}
 +
{{tp|p=32707573|t=2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.|pdf=|usr=014}}
 +
{{tp|p=32698191|t=2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.|pdf=|usr=014}}
 +
{{tp|p=32698190|t=2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32668443|t=2020. Potently neutralizing and protective human antibodies against SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32694847|t=2020. Coronavirus vaccines get a biotech boost.|pdf=|usr=014}}
 +
{{tp|p=32667989|t=2020. COVID-19 and tobacco - more questions than answers.|pdf=|usr=014}}
 +
{{tp|p=32679589|t=2020. Supplementation with vitamin D in the COVID-19 pandemic?|pdf=|usr=014}}
 +
{{tp|p=32653930|t=2020. Dietary recommendations during the COVID-19 pandemic.|pdf=|usr=014}}
 +
{{tp|p=32677126|t=2020. Efficacy of povidone-iodine to reduce viral load.|pdf=|usr=014}}
 +
{{tp|p=32660339|t=2020. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.|pdf=|usr=014}}
 +
{{tp|p=32677113|t=2020. The cardiovascular effects of treatment with hydroxychloroquine and azithromycin.|pdf=|usr=014}}
 +
{{tp|p=32674177|t=2020. Therapie mit Dexamethason bei Patienten mit COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32674189|t=2020. DZK-Stellungnahme zu Tuberkulose, BCG und COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32699149|t=2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32699147|t=2020. Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.|pdf=|usr=014}}
 +
{{tp|p=32662915|t=2020. Computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.|pdf=|usr=014}}
 +
{{tp|p=32696570|t=2020. Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.|pdf=|usr=014}}
 +
{{tp|p=32698247|t=2020. The effect of BCG vaccine in the era of COVID-19 pandemic.|pdf=|usr=014}}
 +
{{tp|p=32657436|t=2020. Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?|pdf=|usr=014}}
 +
{{tp|p=32720847|t=2020. Is there really room for anti-rheumatic drugs in the treatment of COVID-19?|pdf=|usr=014}}
 +
{{tp|p=32690628|t=2020. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.|pdf=|usr=014}}
  
{{tp|p=32340978|t=2020. The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al.|pdf=|usr=007}}
+
{{tp|p=32691006|t=2020. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.|pdf=|usr=014}}
-rest-
+
{{tp|p=32691005|t=2020. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?|pdf=|usr=014}}
{{tp|p=32229705|t=2020. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections |pdf=|usr=}}
+
{{tp|p=32650788|t=2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.|pdf=|usr=014}}
{{tp|p=32276453|t=2020. Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency  and Similar Future Global Health Threats |pdf=|usr=}}
+
{{tp|p=32682081|t=2020. Fish Oil and Covid-19 Thromboses.|pdf=|usr=014}}
{{tp|p=32325124|t=ä. Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals |pdf=|usr=}}
+
{{tp|p=32661140|t=2020. The SARS-CoV-2 N protein is a good component in a vaccine.|pdf=|usr=014}}
{{tp|p=32312129|t=2020. The role of additive manufacturing and antimicrobial polymers in the COVID-19 pandemic |pdf=|usr=}}
+
{{tp|p=32687267|t=2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.|pdf=|usr=014}}
{{tp|p=32336674|t=ä. COVID-19 Emergency Responders in FDA?s Center for Drug Evaluation and Research |pdf=|usr=}}
+
{{tp|p=32702298|t=2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.|pdf=|usr=014}}
{{tp|p=32356251|t=ä. Medical Toxicology and COVID-19: Our Role in a Pandemic |pdf=|usr=}}
+
{{tp|p=32653520|t=2020. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.|pdf=|usr=014}}
{{tp|p=32243778|t=2020. Ensuring global access to COVID-19 vaccines |pdf=|usr=}}
+
{{tp|p=32679150|t=2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.|pdf=|usr=014}}
{{tp|p=32247324|t=2020. Global coalition to accelerate COVID-19 clinical research in resource-limited settings |pdf=|usr=}}
+
{{tp|p=32679148|t=2020. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.|pdf=|usr=014}}
{{tp|p=32272857|t=2020. Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks |pdf=|usr=}}
+
{{tp|p=32684816|t=2020. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections?|pdf=|usr=014}}
{{tp|p=C7190525|t=2020. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients |pdf=|usr=}}
+
{{tp|p=32703911|t=2020. Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?|pdf=|usr=014}}
{{tp|p=32129977|t=2020. Cell-Membrane-Mimicking Nanodecoys against Infectious Diseases |pdf=|usr=}}
+
{{tp|p=32663741|t=2020. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.|pdf=|usr=014}}
{{tp|p=29115746|t=2018. Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies |pdf=|usr=}}
+
{{tp|p=32683221|t=2020. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll.|pdf=|usr=014}}
{{tp|p=29717819|t=2018. Recent Advances in the Development of Antimicrobial Nanoparticles for Combating Resistant Pathogens |pdf=|usr=}}
+
{{tp|p=32653736|t=2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.|pdf=|usr=014}}
{{tp|p=C7194243|t=ä. Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion |pdf=|usr=}}
+
{{tp|p=32683219|t=2020. Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19.|pdf=|usr=014}}
{{tp|p=32383008|t=ä. The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic |pdf=|usr=}}
+
{{tp|p=32670526|t=2020. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.|pdf=|usr=014}}
{{tp|p=32380052|t=2020. Granulocyte-targeted therapies for airway diseases |pdf=|usr=}}
+
{{tp|p=32668701|t=2020. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.|pdf=|usr=014}}
{{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}}
+
{{tp|p=32663912|t=2020. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.|pdf=|usr=014}}
 +
{{tp|p=32663910|t=2020. The Covid-19 Vaccine-Development Multiverse.|pdf=|usr=014}}
 +
{{tp|p=32665542|t=2020. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.|pdf=|usr=014}}
 +
{{tp|p=32661375|t=2020. Immune-mediated approaches against COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32694244|t=2020. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.|pdf=|usr=014}}
 +
{{tp|p=32681986|t=2020. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32655899|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=014}}
 +
{{tp|p=32679784|t=2020. Immunologic Effects of Vitamin D on Human Health and Disease.|pdf=|usr=014}}
 +
{{tp|p=32691007|t=2020. Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.|pdf=|usr=014}}
 +
{{tp|p=32671131|t=2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32704455|t=2020. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.|pdf=|usr=014}}
 +
{{tp|p=32700247|t=2020. Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32653650|t=2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32653649|t=2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.|pdf=|usr=014}}
 +
{{tp|p=32675044|t=2020. Contribution of traditional Chinese medicine to the treatment of COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32706790|t=2020. Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios.|pdf=|usr=014}}
 +
{{tp|p=32706783|t=2020. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.|pdf=|usr=014}}
 +
{{tp|p=32701969|t=2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.|pdf=|usr=014}}
 +
{{tp|p=32661586|t=2020. COVID-19 and purinergic signaling: the need for investigation.|pdf=|usr=014}}
 +
{{tp|p=32702730|t=2020. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.|pdf=|usr=014}}
 +
{{tp|p=32702732|t=2020. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.|pdf=|usr=014}}
 +
{{tp|p=32702715|t=2020. Worldwide inverse correlation between Bacille Calmette-Guerin immunization and COVID-19 morbidity and mortality.|pdf=|usr=014}}
 +
{{tp|p=32702731|t=2020. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.|pdf=|usr=014}}
 +
{{tp|p=32670785|t=2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.|pdf=|usr=014}}
 +
{{tp|p=32659271|t=2020. Pros and cons of corticosteroid therapy for COVID-19 patients.|pdf=|usr=014}}
 +
{{tp|p=32696884|t=2020. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis.|pdf=|usr=014}}
 +
{{tp|p=32696862|t=2020. Use of remdesivir for patients with Covid-19: a review article.|pdf=|usr=014}}
 +
{{tp|p=32696811|t=2020. Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports.|pdf=|usr=014}}
 +
{{tp|p=32691011|t=2020. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.|pdf=|usr=014}}
 +
{{tp|p=32661235|t=2020. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.|pdf=|usr=014}}
 +
{{tp|p=32660307|t=2020. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.|pdf=|usr=014}}
 +
{{tp|p=32695804|t=2020. Cellular Therapy: Shafts of Light Emerging for COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32698898|t=2020. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32678017|t=2020. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.|pdf=|usr=014}}
 +
{{tp|p=32696426|t=2020. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.|pdf=|usr=014}}
 +
{{tp|p=32661867|t=2020. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32641644|t=2020. COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?|pdf=|usr=014}}
 +
{{tp|p=32653199|t=2020. Immunomodulation for the management of corona virus disease (COVID-19).|pdf=|usr=014}}
 +
{{tp|p=32631501|t=2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?|pdf=|usr=014}}
 +
{{tp|p=32620409|t=2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.|pdf=|usr=014}}
 +
{{tp|p=32694044|t=2020. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.|pdf=|usr=014}}
 +
{{tp|p=32694043|t=2020. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.|pdf=|usr=014}}
 +
{{tp|p=32684483|t=2020. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.|pdf=|usr=014}}
 +
{{tp|p=32660611|t=2020. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=014}}
 +
{{tp|p=32682360|t=2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.|pdf=|usr=014}}
 +
{{tp|p=32654907|t=2020. Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.|pdf=|usr=014}}
 +
{{tp|p=32653276|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.|pdf=|usr=014}}
 +
{{tp|p=32620375|t=2020. Contingent assessment of the COVID-19 vaccine.|pdf=|usr=014}}
 +
{{tp|p=32684499|t=2020. Planning for COVID-19 vaccines safety surveillance.|pdf=|usr=014}}
 +
{{tp|p=32698423|t=2020. Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.|pdf=|usr=014}}
 +
{{tp|p=32664505|t=2020. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis.|pdf=|usr=014}}
 +
{{tp|p=32666898|t=2020. Images in Vascular Medicine: Peripheral artery thrombosis in critically ill patients with COVID-19.|pdf=|usr=014}}
 +
{{tp|p=32691699|t=2020. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.|pdf=|usr=014}}
 +
{{tp|p=32696396|t=2020. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.|pdf=|usr=014}}
 +
{{tp|p=32698440|t=2020. Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.|pdf=|usr=014}}

Version vom 3. August 2020, 14:45 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

current items will be put into the subsections.







32628145 2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
32634024 2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.
32646061 2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?
32638906 2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.
32645994 2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.
32649880 2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.
32641681 2020. Is hydroxychloroquine beneficial for COVID-19 patients?
32638908 2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.
32646869 2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.
32646499 2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.
32631373 2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.
32620147 2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.
32618691 2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.
32640414 2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.
32634717 2020. Application of Artificial Intelligence in COVID-19 drug repurposing.
32639233 2020. Concentration-dependent mortality of chloroquine in overdose.
32619390 2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.
32615862 2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.
32616599 2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.
32640331 2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.
32621202 2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.
32638628 2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.
32622993 2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.
32621881 2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).
32641876 2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.
32641874 2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
32643111 2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.
32640381 2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
32642806 2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
32645633 2020. An update on antiviral antibody-based biopharmaceuticals.
32645632 2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
32634603 2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.
32646770 2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
32639711 2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.
32619190 2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.
32648245 2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.
32628223 2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.
32640172 2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.
32634026 2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.
32628535 2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.
32647027 2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.
32632035 2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
32632034 2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.
32632030 2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.
32620597 2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
32641296 2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
32631826 2020. Clinical trials of repurposed antivirals for SARS-CoV-2.
32639103 2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.
32644876 2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.
32646867 2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.
32631851 2020. Urgent call for greater multilateralism and coordination of covid-19 trials.
32631850 2020. Covid-19: research methods must be flexible in a crisis.
32620554 2020. Dexamethasone in the management of covid -19.
32611587 2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.
32641344 2020. COVID-19 clinical trials: see it big and keep it simple.
32639062 2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.
32627226 2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?
32645204 2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.
32621754 2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
32639031 2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?
32640179 2020. Current Therapies Under Investigation for COVID-19.
32633733 2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.
32613971 2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.
32621392 2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.
32640049 2020. Immune checkpoint inhibition in the era of COVID-19.
32640019 2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.
32628748 2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.
32648959 2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
32634894 2020. Smoking in critically ill patients with COVID-19: the Australian experience.
32628049 2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.
32619167 2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.
32634080 2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).
32634079 2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.
32628591 2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.
32648845 2020. Therapeutic targets and computational approaches on drug development for COVID-19.
32621718 2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.
32643448 2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.
32632960 2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.
32629169 2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.
32616659 2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.
32616658 2020. BET 1: Lopinavir-ritonavir and COVID-19.
32641191 2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.
32648935 2020. SGLT2 inhibition and COVID-19: The road not taken.
32620680 2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?
32631083 2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
32643980 2020. Predictor of poor prognosis of COVID-19 patients----liver injury.
32649840 2020. Liver injury in severe COVID-19 infection: current insights and challenges.
32639083 2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.
32645727 2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?
32643512 2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.
32633162 2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.
32643997 2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.
32615877 2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.
32649272 2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?
32643552 2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.
32643550 2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.
32643529 2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.
32627715 2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.
32627689 2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
32619162 2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.
32619134 2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.
32618198 2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.
32643158 2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.
32643200 2020. Convalescent plasma therapy in patients with COVID-19.
32647045 2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.
32644254 2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.
32644224 2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.
32644208 2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.
32633865 2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.
32633831 2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.
32621621 2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.
32617989 2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.


32634602 2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.
32629115 2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.
32619764 2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.
32634589 2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.
32623082 2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.
32623080 2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.
32629817 2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.
32617855 2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.
32627127 2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
32623068 2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.
32634126 2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.
32629768 2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
32630746 2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.
32622963 2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().
32622008 2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.
32636240 2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.
32611687 2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
32627442 2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.
32638109 2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?
32646487 2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.
32635935 2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.
32631442 2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).
32650019 2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.
32629788 2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.
32610445 2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).
32634550 2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.
32641037 2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.
32647131 2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
32648153 2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.
32641560 2020. COVID-19 and vitamin D deficiency, a fatal combination?
32645974 2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.
32619723 2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?
32622723 2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.
32629137 2020. Ultraviolet-based Biophotonic Technologies and COVID-19.
32641511 2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.
32621829 2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".
32638884 2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?
32616763 2020. A candidate multi-epitope vaccine against SARS-CoV-2.
32638647 2020. Alternative management of Covid-19 infection.
32636116 2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.
32645478 2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.
32629139 2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
32635353 2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
32640619 2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.
32635180 2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.
32621841 2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
32629804 2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
32620700 2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.
32623965 2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?
32628262 2020. The Development of COVID-19 Vaccines: Safeguards Needed.
32628244 2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.
32614442 2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.
32613691 2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.
32613660 2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.
32619276 2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?
32619669 2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.
32633860 2020. Safety of Plasma Infusions in Parkinson's Disease.
32649078 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
32649077 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649076 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649075 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32649074 2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.
32643410 2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.
32636505 2020. COVID-19 platform trial delivers.
32623442 2020. Going back in time for an antibody to fight COVID-19.
32645305 2020. Golden Anniversary of the Nicotinic Receptor.
32618794 2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).
32615642 2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.
32613637 2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.
32648294 2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.
32647056 2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).
32648313 2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
32614102 2020. Using heat to kill SARS-CoV-2.
32646977 2020. Can interferons stop COVID-19 before it takes hold?
32649367 2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.
32619318 2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.
32627216 2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
32639598 2020. SARS-CoV2 and immunosuppression: a double-edged sword.
32629531 2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.
32614684 2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.


32388537 2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).
32532959 2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.
32423553 2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.
32531235 2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.
32430279 2020. Gut microbiota and Covid-19- possible link and implications.
32416259 2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.
32558150 2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.
32585135 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
32546195 2020. Micronutrient status of COVID-19 patients: a critical consideration.
32559343 2020. Rationale for targeting Complement in COVID-19.
32543705 2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.
32592394 2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.
32590326 2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.
32562814 2020. Statins and other drugs: Facing COVID-19 as a vascular disease.
32424591 2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?
32598884 2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.
32481719 2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.
32534506 2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
32600316 2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.
32537478 2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.
32595361 2020. Gut-lung axis and dysbiosis in COVID-19.
32591496 2020. Door to the cell for COVID-19 opened, leading way to therapies.
32602262 2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
32555145 2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.
32594085 2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.
32582574 2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.
32545271 2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.

32593832 2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.


32573788 2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.
32551652 2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.
32551648 2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
32571797 2020. Identification of common deletions in the spike protein of SARS-CoV-2.
32606248 2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.
32602627 2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.


32417594 2020. Supplements for COVID-19: A modifiable environmental risk.


32167678 2020. Evaluation of glycoprotein E subunit and live attenuated varicella-zoster virus vaccines formulated with a single-strand RNA-based adjuvant.
32405233 2020. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection.
32400027 2020. Immunological fortification at our barrier organs: Protecting us as we age.
25762305 2015. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus.
32621997 2020. Which QTc correction formulae (Bazett, Framingham, or Fridericia) to use for Hydroxychloroquine induced QTc prolongation?
32621996 2020. HCQ induced QT prolongation- Primum non nocere.
32651941 2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.
32645630 2020. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
32430515 2020. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung.
32654006 2020. Emerging pharmacological therapies for ARDS: COVID-19 and beyond.
32303896 2020. Therapeutic and prophylactic potential of anti-microbial peptides against coronaviruses.
32622261 2020. Current Status of COVID-19 Therapies and Drug Repositioning Applications.
32652194 2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.
32339702 2020. Role of phototherapy in the era of biologics.
32622513 2020. The roles of PPARgamma and its agonists in autoimmune diseases: A comprehensive review.
32624376 2020. Ayurvedic clinical profile of COVID-19 - A preliminary report.
32637368 2020. COVID-19: Introducing Low Dose Radiation as an Effective Treatment for Pneumonia that Shouldn't Induce Selective Pressure and New Mutations.
32375574 2020. Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.
32306854 2020. Novel guanosine derivatives against MERS CoV polymerase: An in silico perspective.
18442051 2008. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.
32655741 2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.
32617428 2020. Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.
15693056 2005. SARS-CoV protease inhibitors design using virtual screening method from natural products libraries.
32594451 2020. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
32535155 2020. The stress-inducible molecular chaperone GRP78 as potential therapeutic target for coronavirus infection.
32652164 2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
28864360 2018. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
18324609 2008. Metabolite identification of arbidol in human urine by the study of CID fragmentation pathways using HPLC coupled with ion trap mass spectrometry.
32398885 2020. How materials can beat a virus.
32398884 2020. Materials Science in the time of Coronavirus.
32410212 2020. Acute kidney injury is associated with the mortality of coronavirus disease 2019.
32628003 2020. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
32617527 2020. Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV).
32301512 2020. Drug repositioning: a brief overview.
32653646 2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.
32624302 2020. A case of cytokine hemofiltration and extracorporeal life support as treatment of coronavirus disease 2019 (COVID-19) respiratory failure.
32642277 2020. Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial.
32642225 2020. Addressing the "What do we have to lose? Just give the drug" rationale: making the case for clinical trials and against off-label use in COVID-19.
32576276 2020. "Right-to-Try" experimental drugs: an overview.
32650788 2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.
32188729 2020. Coronavirus Endoribonuclease and Deubiquitinating Interferon Antagonists Differentially Modulate the Host Response during Replication in Macrophages.
18199635 2008. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
32493486 2020. Alveolar lipids in pulmonary disease. A review.
32653736 2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.
32423569 2020. Del empirismo a la evidencia cientifica en el tratamiento con antiviricos en los casos graves de infeccion por coronavirus en tiempos de epidemia.
32599077 2020. Coronavirus vaccine-associated lung immunopathology-what is the significance?
32600307 2020. The alpha7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-induced acute inflammatory lung injury by alleviating the accumulation of HMGB1 in the airways and the circulation.
32579882 2020. Preparing for Pandemics: RNA Vaccines at the Forefront.
32516954 2020. Antiviral Effects of Plant-Derived Essential Oils and Their Components: An Updated Review.
32325742 2020. Advances on Antiviral Activity of Morus spp. Plant Extracts: Human Coronavirus and Virus-Related Respiratory Tract Infections in the Spotlight.
32295300 2020. Natural Bioactive Compounds from Fungi as Potential Candidates for Protease Inhibitors and Immunomodulators to Apply for Coronaviruses.
32459913 2020. Remdesivir - An Important First Step.
32636478 2020. Dexamethasone to the rescue.
32409740 2020. Type I and type III interferon in opposition?
32378128 2020. Drug repurposing in cardiology.
32651844 2020. The 'president's drug'.
32643072 2020. An antiarrhythmic approach to hydroxychloroquine-induced QT prolongation.
32474177 2020. Nicotinic acetylcholine receptors regulate clustering, fusion and acidification of the rat brain synaptic vesicles.
32529044 2020. Better patient identification could help fight the coronavirus.
32655899 2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.
32579137 2020. New international guidance on quality, safety and efficacy of DNA vaccines.
32579135 2020. WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019.
32536809 2020. Is a vitamin D fortification strategy needed?
32349265 2020. Vitamin D and Immunity in Infants and Children.
32344708 2020. A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis.
32325790 2020. Key Vitamin D Target Genes with Functions in the Immune System.
32325778 2020. Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations.
32290296 2020. The Role of Selenium in Health and Disease: Emerging and Recurring Trends.
32617169 2020. Hydroxychloroquine-induced Stevens-Johnson syndrome in COVID-19: a rare case report.
32551127 2020. Covering coronavirus-emerging tools for the fight against the common enemy.
32653463 2020. Vaccines for COVID-19: The current state of play.
32630514 2020. Preliminary Virtual Screening Studies to Identify GRP78 Inhibitors Which May Interfere with SARS-CoV-2 Infection.
32590098 2020. Global research on artemisinin and its derivatives: Perspectives from patents.
32653650 2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
32653649 2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.
32384116 2020. Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.
32350142 2020. News Feature: To counter the pandemic, clinicians bank on repurposed drugs.
17567736 2007. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine.
17340634 2007. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin.
32540609 2020. Possible beneficial role of throat gargling in the coronavirus disease pandemic.
32653040 2020. The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.
32616298 2020. Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?
32636066 2020. Electrocardiographic/QT interval monitoring with a portable device in hospitalized patients with COVID-19: a protocol proposal.
32593625 2020. Melatonin, coronavirus, cardiovascular disease, and the geriatric emergency: let's use everything we have!
32622732 2020. The presence of heart disease worsens prognosis in patients with COVID-19.
32550880 2020. Recommandations EMA sur l'usage compassionnel du remdesivir.
32537031 2020. Hochdosiertes Chloroquin bei COVID-19 gefahrlich.
32577525 2020. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques.
32179788 2020. Ginkgolic acid inhibits fusion of enveloped viruses.
32448377 2020. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury.
32318958 2020. How to "Detronize" Virus in Crown - Questions to Current Stem Cell Therapies.
32537523 2020. An aurora of natural products-based drug discovery is coming.
32612804 2020. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents.
32641977 2020. Bioengineering tools to speed up the discovery and preclinical testing of vaccines for SARS-CoV-2 and therapeutic agents for COVID-19.
32653199 2020. Immunomodulation for the management of corona virus disease (COVID-19).
32631501 2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
32620409 2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.
32636114 2020. Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption.
32565057 2020. The true historical origin of convalescent plasma therapy.
32542716 2020. Effective coronavirus reduction by various production steps during the manufacture of plasma-derived medicinal products.
32333396 2020. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
32533558 2020. Convalescent plasma - this is no time for competition.
24117799 2014. Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.
32504825 2020. Innovative highlights of clinical drug trial design.
32593869 2020. Traditional Chinese Herbal Medication for corona-virus 2019.
32340868 2020. Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?
32651113 2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.
32313527 2020. Vacunas contra el coronavirus.
32395638 2020. Chloroquine/Hydroxychloroquine Overdose.
32240549 2020. Pivotal role of convalescent plasma in managing emerging infectious diseases.
12800213 2003. Advances in clinical diagnosis and treatment of severe acute respiratory syndrome.


32596616 2020. Extraction, Characterization, and Anticoagulant Activity of a Sulfated Polysaccharide from Bursatella leachii Viscera.
32579890 2020. Targeting drug delivery in the vascular system: Focus on endothelium.
32654004 2020. Comments on: The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality.
32653224 2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?
32624192 2020. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
32502485 2020. Hydroxychloroquine for Coronavirus: The Urgent Need for a Moratorium on Prescriptions.
32653550 2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
32606531 2020. Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?
32637086 2020. A severe refractory COVID-19 patient responding to convalescent plasma; A case series.
32653425 2020. Does androgen deprivation therapy protect against severe complications from COVID-19?
32653452 2020. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
32607398 2020. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol.
32600868 2020. Glucose-6-Phosphate Dehydrogenase Deficiency: An Actionable Risk Factor for Patients with COVID-19?
32611537 2020. Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.
32603888 2020. Clinical implications of nicotine as an antimicrobial agent and immune modulator.
32626733 2020. Effect of Thymoquinone on Acute Kidney Injury Induced by Sepsis in BALB/c Mice.
32443566 2020. Metformin: Sentinel of the Epigenetic Landscapes That Underlie Cell Fate and Identity.
32120929 2020. Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63.
32629280 2020. COVID19 inhibitors: A prospective therapeutics.
22446091 2012. Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.
32297972 2020. Built-in RNA-mediated chaperone (chaperna) for antigen folding tailored to immunized hosts.
30597533 2019. Synthetic biology for bioengineering virus-like particle vaccines.
26212697 2015. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.
20809484 2010. Generating stable Chinese hamster ovary cell clones to produce a truncated SARS-CoV spike protein for vaccine development.
16321039 2005. Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.
32493296 2020. Network pharmacology to dissect the mechanisms of Yinlai Decoction for pneumonia.
32601089 2020. Food is medicine: actions to integrate food and nutrition into healthcare.
32444705 2020. Hydrogen peroxide mouthwash.
32591697 2020. New video will promote silver diamine fluoride to children.
32591690 2020. Chlorhexidine has an antiviral effect against viruses.
32591675 2020. Virucidal activity.
32591671 2020. Povidone iodine gargle and mouthwash.
32307721 2020. Extensive hard palate hyperpigmentation associated with chloroquine use.
32615072 2020. Ivermectin: potential candidate for the treatment of Covid 19.
32645327 2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
32643603 2020. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.
32442424 2020. Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism.
32544459 2020. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment.
32402267 2020. Metformin Enhances Autophagy and Normalizes Mitochondrial Function to Alleviate Aging-Associated Inflammation.
32612152 2020. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
32629149 2020. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19.
16511823 2006. Deciphering the biosynthetic codes for the potent anti-SARS-CoV cyclodepsipeptide valinomycin in Streptomyces tsusimaensis ATCC 15141.
23788528 2013. Synergistic inhibitor binding to the papain-like protease of human SARS coronavirus: mechanistic and inhibitor design implications.
32533956 2020. Impact of Small-N Studies During a Pandemic.
32505301 2020. Adjunctive Therapies in ARDS: The Disconnect Between Clinical Trials and Clinical Practice.
32632717 2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.
32405143 2020. Remdesivir - A giant step, or a tiptoe?
32512231 2020. Tuberculosis sepsis after tocilizumab treatment.
32651020 2020. COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.
32613089 2020. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multi-centric prospective trial.
32402130 2020. What Do We Know About Remdesivir Drug Interactions?
32623357 2020. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
32661494 2020. Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.
32653043 2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32426753 2020. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.
32637266 2020. Lithium Toxicity in Two Coronavirus Disease 2019 (COVID-19) Patients.
32626630 2020. Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review.
32637278 2020. Packed Red Blood Cell Transfusion as a Potential Treatment Option in COVID-19 Patients With Hypoxemic Respiratory Failure: A Case Report.
32656044 2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.
32615514 2020. Docking approaches for modeling multi-molecular assemblies.
32399388 2020. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview.
32616467 2020. Mesenchymal stem cells in the fight against viruses: Face to face with the invisible enemy.
32616381 2020. A critical evaluation of glucocorticoids in the management of severe COVID-19.
32636055 2020. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
32227604 2020. Repurposing therapeutic agents and herbal medicines to defeat viral nemesis.
32655654 2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.
32636919 2020. Can vitamins and/or supplements provide hope against coronavirus?
32427191 2019. Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.
32619884 2020. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
32506216 2020. Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase(R).
32653152 2020. Waste in COVID-19 clinical trials conducted in western Europe.
32651040 2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.
32652408 2020. Natural and nature-inspired stilbenoids as antiviral agents.
32616594 2020. Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon lambda In Vitro And In Mice.
32591664 2020. Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?
32587388 2020. Prevalence of hydroxychloroquine retinopathy using 2018 Royal College of Ophthalmologists diagnostic criteria.
32427967 2020. Hydroxychloroquine hitting the headlines-retinal considerations.
32653511 2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.
32655584 2020. Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2.
32655583 2020. Vitamin D Supplementation: A Potential Approach for Coronavirus/COVID-19 Therapeutics?
32655582 2020. Targeting the NLRP3 Inflammasome in Severe COVID-19.
32655581 2020. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
32655578 2020. Three Decades of Interferon-beta in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
32655577 2020. Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients.
32636851 2020. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).
32612616 2020. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
32612613 2020. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
32582186 2020. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.
32174911 2020. Quantitative Proteomic Analysis Reveals Antiviral and Anti-inflammatory Effects of Puerarin in Piglets Infected With Porcine Epidemic Diarrhea Virus.
32651936 2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.
32655532 2020. Biocides and Novel Antimicrobial Agents for the Mitigation of Coronaviruses.
32636755 2020. Potential Benefits of Tryptophan Metabolism to the Efficacy of Tocilizumab in COVID-19.
32636754 2020. A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.
32390855 2020. Traditional Chinese Medicine and Gut Microbiome: Their Respective and Concert Effects on Healthcare.
32636763 2020. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease.
32636762 2020. Activation of Ang-(1-7)/Mas Receptor Is a Possible Strategy to Treat Coronavirus (SARS-CoV-2) Infection.
32352313 2020. Incipient need of targeting airway remodeling using advanced drug delivery in chronic respiratory diseases.
32647807 2020. The Emerging Role of Convalescent Plasma in the Treatment of COVID-19.
32606420 2020. The value of targeting recombination as a strategy against coronavirus diseases.



32665809 2020. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
32665808 2020. Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment.
32667191 2020. Hard Nanomaterials in Time of Viral Pandemics.
32717094 2020. Cannabis terapeutico y COVID-19: entre el oportunismo y la infoxicacion.
32711735 2020. Reverse genetic systems: Rational design of coronavirus live attenuated vaccines with immune sequelae.
32705585 2020. Associations between hypovitaminosis D and COVID-19: a narrative review.
32653224 2020. BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?
32687406 2020. Inhibiting Fusion with Cellular Membrane System: Therapeutic Options to Prevent Severe Acute Respiratory Syndrome Coronavirus-2 Infection.
32653550 2020. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better?
32673060 2020. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.
32673059 2020. The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale.
32667853 2020. Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.
32653425 2020. Does androgen deprivation therapy protect against severe complications from COVID-19?
32692238 2020. Tongue diagnosis and treatment in traditional Chinese medicine for severe COVID-19: a case report.
32660993 2020. Safety, pharmacokinetics, and activity of high-dose ivermectin and chloroquine against the liver-stage of Plasmodium cynomolgi infection in Rhesus Macaques.
32708578 2020. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19.
32679055 2020. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
32659293 2020. Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection.
32659292 2020. Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro.
32660794 2020. Response to: Amantadine Treatment for People with COVID-19.
32682671 2020. Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.
32710969 2020. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
32688139 2020. PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open.
32679775 2020. Deamidated Human Triosephosphate Isomerase is a Promising Druggable Target.
32665234 2020. Drug treatments affecting ACE2 in COVID-19 infection: a systematic review protocol.
32717399 2020. Purinergic signaling in infectious diseases of the central nervous system.
32679175 2020. Regional differences in use of immune-modulating catechins should be investigated regarding COVID-19.
32679174 2020. Reply to the Letter to the Editor: Regional differences in dietary use of immune-modulating catechins should be investigated regarding COVID-19.
32615072 2020. Ivermectin: potential candidate for the treatment of Covid 19.
32717278 2020. The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients.
32643141 2020. Ion channel inhibition against COVID-19: A novel target for clinical investigation.
32645327 2020. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.
32714563 2020. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro.
32707096 2020. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.
32668216 2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
32711111 2020. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
32710890 2020. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study.
32676976 2020. Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.
32632717 2020. In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.
32665783 2020. Current strategies against COVID-19.
32667534 2020. Pandemia de COVID19: implicacoes para (in)seguranca alimentar e nutricional.
32661912 2020. Tocilizumab, Adipokines and Severe Complications of COVID-19.
32661911 2020. Authors' Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19.
32707089 2020. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine.
32673711 2020. mTORC inhibitor Sirolimus deprograms monocytes in "cytokine storm" in SARS-CoV2 secondary hemophagocytic lymphohistiocytosis- like syndrome.
32663514 2020. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?: In reply to, 'COVID-19: Immunology and treatment options', Felsenstein, Herbert McNamara et al. 2020'.
32675166 2020. COVID-19, hydroxychloroquine and the eighth alternative.
32717568 2020. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
32705604 2020. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
32709544 2020. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
32668460 2020. COVID-19 Therapeutics: Making Sense of It All.
32662982 2020. Calcium Channel Blockers: A Possible Potential Therapeutic Strategy for the Treatment of Alzheimer's Dementia Patients with SARS-CoV-2 Infection.
32687696 2020. Old drugs for a new virus: repurposed approaches for combating COVID-19.
32686128 2020. Montelukast in children with allergic rhinitis amid COVID-19 pandemic.
32696443 2020. The Role of Hyperbaric Oxygen Treatment for COVID-19: A Review.
32716768 2020. The Regulation of COVID-19 "Challenge" Studies.
32709838 2020. Unusual Early Recovery of a Critical COVID-19 Patient After Administration of Intravenous Vitamin C.
32661220 2020. First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection.
32694294 2020. Nutrition Support in the ICU-A Refresher in the Era of COVID-19.
32668178 2020. Inhaled Corticosteroids and COVID-19.
32668164 2020. Reply to: Inhaled Corticosteroids and COVID-19.
32711585 2020. More Studies are Needed on the Link between Metformin and Decreased Mortality in Diabetic COVID-19 Patients.
32705976 2020. Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials.
32663348 2020. Current status of COVID-19 (pre)clinical vaccine development.
32692580 2020. Repurposing Existing Drugs for the Treatment of COVID-19.
32687756 2020. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.
32661006 2020. Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
32686943 2020. Potential role of Bacillus Calmette-Guerin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.
32713288 2020. Chloroquine in fighting COVID-19: good, bad, or both?
32692801 2020. COVID-19 Docking Server: A meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19.
32663708 2020. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.
32699011 2020. Intensive immunosuppression reduces deaths in covid-19-associated cytokine storm syndrome, study finds.
32698999 2020. Are we responsible for the racial inequalities of covid-19?
32665225 2020. Covid-19: Experts criticise claim that remdesivir cuts death rates.
32693436 2020. Model-Informed Drug Repurposing: Viral Kinetic Modeling to Prioritize Rational Drug Combinations for COVID-19.
32692462 2020. ABNORMAL LABORATORY FINDINGS AND PLASMA CONCENTRATION MONITORING OF LOPINAVIR AND RITONAVIR IN COVID-19.
32687645 2020. Clinical outcomes and adverse events in patients hospitalised with COVID -19, treated with off- label hydroxychloroquine and azithromycin.
32656822 2020. Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
32652563 2020. Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
32713358 2020. COVID-19 and Misinformation: How an Infodemic Fueled the prominence of Vitamin D.
32703328 2020. THE RATIONALE FOR A MULTI-STEP THERAPEUTIC APPROACH BASED ON ANTIVIRALS, DRUGS, AND NUTRIENTS WITH IMMUNOMODULATORY ACTIVITY IN PATIENTS WITH CORONAVIRUS-SARS2-INDUCED DISEASE OF DIFFERENT SEVERITY.
32700336 2020. Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19.
32681537 2020. Safety perspectives on presently considered drugs for the treatment of COVID-19.
32671829 2020. Targeting zinc metalloenzymes in COVID-19.
32713374 2020. Clozapine treatment and risk of COVID-19.
32662814 2020. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses.
32717117 2020. Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main Protease of SARS-CoV-2.
32700795 2020. Targeting SARS-CoV-2 RBD interface: a supervised computational data-driven approach to identify potential modulators.
32702997 2020. IL-6 Blockade and QTc Prolongation in COVID-19.
32671847 2020. In response to: Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.
32710937 2020. Micronutrients as immunomodulatory tools for COVID-19 management.
32706859 2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care.
32674126 2020. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial.
32671407 2020. Long-term outcome of short-course high-dose glucocorticoids for SARS: a 17-year follow-up in SARS survivors.
32667978 2020. Treatment of COVID-19 - Evidence-Based or Personalized Medicine?
32651997 2020. Tocilizumab for treatment of mechanically ventilated patients with COVID-19.
32687630 2020. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
32674594 2020. Endpoints for randomized controlled clinical trials for COVID-19 treatments.
32666816 2020. Highly efficient clinical trial designs for reliable screening of under-performing treatments: Application to the COVID-19 Pandemic.
32650672 2020. Clinical trials in the time of a pandemic.
32650671 2020. Editorial: Clinical trial design in the era of COVID-19.
32651961 2020. Updates on the Pharmacology of Chloroquine against Coronavirus Disease 2019 (COVID-19): A Perspective on its Use in the General and Geriatric Population.
32675717 2020. Role for antimalarials in the management of COVID-19.
32674732 2020. Ligand- and structure-based virtual screening of Lamiaceae diterpenes with potential activity against a novel coronavirus (2019-nCoV).
32686260 2020. Insights in chloroquine action: perspectives and implications in Malaria and COVID-19.
32692700 2020. Plasma-derived therapy: can the survivors of COVID-19 help the defenseless?
32690491 2020. Dexamethasone for COVID-19: preliminary findings.
32705683 2020. High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection.
32688337 2020. Growth hormone therapy at the time of Covid-19 pandemic: adherence and drug supply issues.
32706089 2020. Potential usefulness of pentoxifylline, a non-specific phosphodiesterase inhibitor with anti-inflammatory, anti-thrombotic, antioxidant, and anti-fibrogenic properties, in the treatment of SARS-CoV-2.
32706087 2020. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients.
32700604 2020. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.


32658735 2020. Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach.
32698853 2020. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.
32693829 2020. Chinese herbal experience for the 2019 novel coronavirus.
32690059 2020. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials.
32684169 2020. Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study.
32682440 2020. Blocking IL-1 to prevent respiratory failure in COVID-19.
32680535 2020. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.
32664996 2020. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation.
32653043 2020. Administration of umbilical cord mesenchymal stem cells in patients with severe COVID-19 pneumonia.
32653015 2020. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
32656044 2020. Pulse Therapy With Corticosteroids and Intravenous Immunoglobulin in the Management of Severe Tocilizumab-Resistant COVID-19: A Report of Three Clinical Cases.
32661859 2020. Can Vitamins, as Epigenetic Modifiers, Enhance Immunity in COVID-19 Patients with Non-communicable Disease?
32665127 2020. Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
32683320 2020. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).
32696429 2020. Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
32696108 2020. Pharmaco-Immunomodulatory Therapy in COVID-19.
32655654 2020. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments.
32691021 2020. Tocilizumab improves survival in patients with persistent hypoxia in severe COVID-19 pneumonia.
32662949 2020. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis.
32696234 2020. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.
32653152 2020. Waste in COVID-19 clinical trials conducted in western Europe.
32651040 2020. Linking hydroxychloroquine to hemolysis in a 'suspected' glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection - a critical appraisal.
32693294 2020. Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.
32668312 2020. A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection.
32682787 2020. Advances in the possible treatment of COVID-19: A review.
32700671 2020. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
32707160 2020. An overview of safety assessment of the medicines currently used in the treatment of COVID-19 disease.
32679367 2020. Selenium - associated gene signatures within the SARS-CoV-2 - host genomic interaction interface.
32653511 2020. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.
32714335 2020. Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.
32695123 2020. GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response.
32670297 2020. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
32705405 2020. Traditional Chinese medicine for combating COVID-19.
32651936 2020. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China.
32714938 2020. Physical Exercise Potentials Against Viral Diseases Like COVID-19 in the Elderly.
32671084 2020. Randomized Controlled Study Evaluating Efficiency of Low Intensity Transcranial Direct Current Stimulation (tDCS) for Dyspnea Relief in Mechanically Ventilated COVID-19 Patients in ICU: The tDCS-DYSP-COVID Protocol.
32714193 2020. Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection.
32698626 2020. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives.
32672061 2020. Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics.
32662664 2020. N-acetylcysteine as a potential treatment for novel coronavirus disease 2019.
32682763 2020. Association between famotidine use and COVID-19 severity in Hong Kong: a territory-wide study.
32717321 2020. Genomics approaches to synthesis plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.
32703797 2020. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial.
32703791 2020. Complement C5 inhibition in patients with COVID-19 - a promising target?
32676695 2020. Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
32712334 2020. Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study.
32712333 2020. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
32708322 2020. Protective Effect of Epigallocatechin-3-Gallate (EGCG) in Diseases with Uncontrolled Immune Activation: Could Such a Scenario Be Helpful to Counteract COVID-19?
32717282 2020. The Lord of the NanoRings: cyclodextrins and the battle against SARS-CoV-2.
32711037 2020. Radiation Therapy as a Treatment for COVID-19?
32707264 2020. Low-dose Whole-lung Irradiation for COVID-19 Pneumonia: Short Course Results.
32713677 2020. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
32707230 2020. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: implications for treatment with IFN-beta and IFN inducer.
32662677 2020. The combination of artificial intelligence and systems biology for intelligent vaccine design.
32693646 2020. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
32693650 2020. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study.
32693652 2020. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.
32662690 2020. The Use of IV vitamin C for patients with COVID-19: a single center observational study.
32700398 2020. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study.
32657483 2020. Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.
32691927 2020. Drug interactions with potential antivirals used for COVID-19 in older persons.
32701395 2020. Designing Pull Funding For A COVID-19 Vaccine.
32706599 2020. A Social and Behavioral Research Agenda to Facilitate COVID-19 Vaccine Uptake in the United States.
32703069 2020. Promise and challenges in the development of COVID-19 vaccines.
32703064 2020. COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines.
32693665 2020. COVID-19 - Important considerations for developing and using a vaccine.
32663051 2020. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein.
32710535 2020. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?
32713336 2020. Chloroquine as chemoprophylaxis for COVID-19: Will this work?
32673140 2020. Re: Low-dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?
32674673 2020. COVID-19 and Vitamin D deficiency; the two pandemics. Are they correlated?
32666683 2020. COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors.
32673081 2020. Chinese Herbal Medicines During the Covid-19 Pandemic: A Role for Observational Studies.
32659175 2020. Can Vitamin D and L-Cysteine Co-Supplementation Reduce 25(OH)-Vitamin D Deficiency and the Mortality Associated with COVID-19 in African Americans?
32688374 2020. Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.
32720578 2020. Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies.
32720577 2020. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis.
32720571 2020. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2.
32715956 2020. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
32705962 2020. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2.
32705953 2020. Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis.
32705952 2020. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M(pro)) from flavonoid based phytochemical constituents of Calendula officinalis.
32705942 2020. Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors.
32698693 2020. Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads.
32698689 2020. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.
32696720 2020. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.
32696718 2020. Comparative molecular investigation of the potential inhibitors against SARS-CoV-2 main protease: a molecular docking study.
32692306 2020. Virtual screening, molecular dynamics and structure-activity relationship studies to identify potent approved drugs for Covid-19 treatment.
32691697 2020. Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis.
32691680 2020. Cyanobacterial metabolites as promising drug leads against the M(pro) and PL(pro) of SARS-CoV-2: an in silico analysis.
32684114 2020. In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors.
32684109 2020. Targeting virus-host interaction by novel pyrimidine derivative: an in silico approach towards discovery of potential drug against COVID-19.
32679006 2020. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL(pro)).
32677591 2020. The latitude hypothesis, vitamin D, and SARS-Co-V2.
32677545 2020. Approach to the mechanism of action of hydroxychloroquine on SARS-CoV-2: a molecular docking study.
32677533 2020. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach.
32672528 2020. Computer-aided screening for potential TMPRSS2 inhibitors: a combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches.
32666910 2020. Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.
32662333 2020. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
32657643 2020. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).
32697000 2020. Corticosteroids-induced osteonecrosis in COVID-19: a call for caution.
32658005 2020. Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.
32700555 2020. Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
32692858 2020. Stem cell therapies for COVID-19: Strategy and application.
32687345 2020. Structure-based virtual screening to discover potential lead molecules for the SARS-CoV-2 main protease.
32678588 2020. SARS-CoV-2 Main Protease: A Molecular Dynamics Study.
32694358 2020. Hydroxychloroquine and Chloroquine in COVID-19: A Survey of Prescription Patterns Among Rheumatologists.
32700580 2020. Pharmacotherapy in COVID-19 patients: A review of ACE2-raising drugs and their clinical safety.
32677610 2020. Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.
32651218 2020. A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections.
32702095 2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
32651586 2020. Do Not Minimize the Impact of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19.


32666357 2020. Vitamin D and COVID-19.
32685369 2020. Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation.
32677493 2020. Obesity, COVID-19 and immunotherapy: the complex relationship!
32664810 2020. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
32651941 2020. That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.
32656668 2020. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
32683296 2020. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.
32687949 2020. Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal.
32674929 2020. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
32674928 2020. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
32693122 2020. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
32682041 2020. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach.
32698494 2020. Self-Amplifying RNA Viruses as RNA Vaccines.
32674481 2020. Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy.
32691002 2020. A consensus guideline of herbal medicine for coronavirus disease 2019.
32691000 2020. Herbal medicine for the management of COVID-19 during the medical observation period: A review of guidelines.
32652231 2020. Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma.
32652194 2020. Retrospective Analysis of Dermatological Adverse Events Associated with Hydroxychloroquine Reported to the United States Food and Drug Administration.
32674834 2020. Plasma Therapies and Parabiosis in the COVID-19 Era.
32690352 2020. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
32694923 2020. Blood Targets of Adjuvant Drugs Against COVID19.
32713161 2020. The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients.
32677763 2020. Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!
32672454 2020. Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs.
32655741 2020. First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA.
32683212 2020. Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19.
32680687 2020. Therapeutic plasma exchange in life-threatening COVID-19 and associated cytokine release syndrome.
32682930 2020. Could Bordetella pertussis vaccine protect against coronavirus COVID-19?
32695833 2020. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development.
32652164 2020. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
32666875 2020. Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients.
32654098 2020. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
32661074 2020. Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.
32702590 2020. Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation.
32682142 2020. Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists.
32684166 2020. Withaferin A: a potential therapeutic agent against COVID-19 infection.
32685234 2020. Prophetic Medicine-Nigella Sativa (Black cumin seeds) - Potential herb for COVID-19?
32658489 2020. Michael Acceptors Tuned by the Pivotal Aromaticity of Histidine to Block COVID-19 Activity.
32653646 2020. SARS-CoV and SARS-CoV-2 main protease residue interaction networks change when bound to inhibitor N3.
32718719 2020. Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir.
32718715 2020. Reacciones adversas a farmacos utilizados en el tratamiento especifico de la infeccion por SARS-CoV-2.
32712223 2020. Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action.
32712272 2020. Blood nitrate and nitrite modulating nitric oxide bioavailability: potential therapeutic functions in COVID-19.
32708526 2020. Selenium Deficiency Is Associated with Mortality Risk from COVID-19.
32709055 2020. Polymorphism and Selection Pressure of SARS-CoV-2 Vaccine and Diagnostic Antigens: Implications for Immune Evasion and Serologic Diagnostic Performance.
32707768 2020. Two Examples of RNA Aptamers with Antiviral Activity. Are Aptamers the Wished Antiviral Drugs?
32713784 2020. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
32703528 2020. Replica: Ivermectina en COVID-19. inverted question markArgumentum ad ignorantiam?
32719454 2020. Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates.
32652766 2020. The link between Vitamin D and Covid-19: distinguishing facts from fiction.
32662708 2020. SARS-CoV-2 in the first trimester of pregnancy: potential interference in placentation.
32692176 2020. Lung protection by cathepsin C inhibition: a new hope for COVID-19 and ARDS?
32716073 2020. Vitamin D insufficiency as a potential culprit in critical COVID-19 patients.
32691896 2020. Hydroxychloroquine, dermatology, and SARS-CoV-2: Updating an old association.
32691875 2020. SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.
32681650 2020. SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals.
32672860 2020. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
32658304 2020. Montelukast drug activity and potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
32651248 2020. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.
32680924 2020. Oncology-inspired treatment options for COVID-19.
32710111 2020. Vitamin D and COVID-19: Lessons from Spaceflight Analogs.
32705690 2020. Benzothiazoles as potential antiviral agents.
32650355 2020. Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.
32699094 2020. Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
32675436 2020. Tailoring steroids in the treatment of COVID-19 pneumonia assisted by CT scans: Three case reports.
32717043 2020. Pooling Data From Individual Clinical Trials in the COVID-19 Era.
32662848 2020. COVID-19 Antibody Trials Have Begun.
32716474 2020. Setting Expectations for Clinical Research During the COVID-19 Pandemic.
32720612 2020. [Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study)].
32702300 2020. Encouraging results from phase 1/2 COVID-19 vaccine trials.
32702299 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
32663575 2020. Tackling the cytokine storm in COVID-19, challenges and hopes.
32720605 2020. In silico study to evaluate the antiviral activity of novel structures against 3C-like protease of Novel Coronavirus (COVID-19) and SARS-CoV.
32679430 2020. Eicosapentaenoic free fatty acid to treat patients with SARS-Cov2 infection.
32678815 2020. Lopinavir-ritonavir para COVID-19: una revision sistematica viva.
32721082 2020. A Computational Approach to Identify Potential Novel Inhibitors against the Coronavirus SARS-CoV-2.
32696772 2020. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
32658332 2020. COVID-19 in MuSK Myasthenia Gravis: A Case Report.
32706953 2020. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
32706553 2020. Audio Interview: Dexamethasone and Covid-19.
32678530 2020. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.
32668131 2020. Audio Interview: Covid-19 Vaccine Development.
32668109 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.
32668108 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32668107 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32668106 2020. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
32669667 2020. How computational immunology changed the face of COVID-19 vaccine development.
32651581 2020. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.
32669664 2020. COVID-19 vaccine development and a potential nanomaterial path forward.
32699321 2020. Controlling the SARS-CoV-2 spike glycoprotein conformation.
32661423 2020. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
32707573 2020. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
32698191 2020. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
32698190 2020. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
32668443 2020. Potently neutralizing and protective human antibodies against SARS-CoV-2.
32694847 2020. Coronavirus vaccines get a biotech boost.
32667989 2020. COVID-19 and tobacco - more questions than answers.
32679589 2020. Supplementation with vitamin D in the COVID-19 pandemic?
32653930 2020. Dietary recommendations during the COVID-19 pandemic.
32677126 2020. Efficacy of povidone-iodine to reduce viral load.
32660339 2020. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review.
32677113 2020. The cardiovascular effects of treatment with hydroxychloroquine and azithromycin.
32674177 2020. Therapie mit Dexamethason bei Patienten mit COVID-19.
32674189 2020. DZK-Stellungnahme zu Tuberkulose, BCG und COVID-19.
32699149 2020. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
32699147 2020. Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.
32662915 2020. Computer modelling of a potential agent against SARS-Cov-2 (COVID-19) protease.
32696570 2020. Tocilizumab therapy in individuals with COVID-19 infection and hyperinflammatory state.
32698247 2020. The effect of BCG vaccine in the era of COVID-19 pandemic.
32657436 2020. Can medicinal mushrooms have prophylactic or therapeutic effect against COVID-19 and its pneumonic superinfection and complicating inflammation?
32720847 2020. Is there really room for anti-rheumatic drugs in the treatment of COVID-19?
32690628 2020. An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates.


32691006 2020. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective.
32691005 2020. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?
32650788 2020. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development.
32682081 2020. Fish Oil and Covid-19 Thromboses.
32661140 2020. The SARS-CoV-2 N protein is a good component in a vaccine.
32687267 2020. Chloroquine and hydroxychloroquine for the prevention and therapy of COVID-19: new hopes and old cardiovascular concerns.
32702298 2020. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
32653520 2020. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.
32679150 2020. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
32679148 2020. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
32684816 2020. Anti-inflammatory Properties of Stingless Bee Honey May Reduce the Severity of Pulmonary Manifestations in COVID-19 Infections?
32703911 2020. Can Dietary Fatty Acids Affect the COVID-19 Infection Outcome in Vulnerable Populations?
32663741 2020. Prospective vaccination of COVID-19 using shRNA-plasmid-LDH nanoconjugate.
32683221 2020. Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll.
32653736 2020. Surfactant-based prophylaxis and therapy against COVID-19: A possibility.
32683219 2020. Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19.
32670526 2020. Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients.
32668701 2020. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
32663912 2020. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
32663910 2020. The Covid-19 Vaccine-Development Multiverse.
32665542 2020. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing.
32661375 2020. Immune-mediated approaches against COVID-19.
32694244 2020. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
32681986 2020. Harnessing nitric oxide for preventing, limiting and treating the severe pulmonary consequences of COVID-19.
32655899 2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.
32679784 2020. Immunologic Effects of Vitamin D on Human Health and Disease.
32691007 2020. Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options-A Critical Review of the Evidence.
32671131 2020. Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19.
32704455 2020. Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide.
32700247 2020. Cepharanthine: a review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19.
32653650 2020. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
32653649 2020. Analysis on the current quality standards of Chinese materia Medica used in COVID-19 prevention and treatment.
32675044 2020. Contribution of traditional Chinese medicine to the treatment of COVID-19.
32706790 2020. Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios.
32706783 2020. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
32701969 2020. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease.
32661586 2020. COVID-19 and purinergic signaling: the need for investigation.
32702730 2020. In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data.
32702732 2020. Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.
32702715 2020. Worldwide inverse correlation between Bacille Calmette-Guerin immunization and COVID-19 morbidity and mortality.
32702731 2020. Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.
32670785 2020. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.
32659271 2020. Pros and cons of corticosteroid therapy for COVID-19 patients.
32696884 2020. Effects of four types of integrated Chinese and Western medicines for the treatment of COVID-19 in China: a network meta-analysis.
32696862 2020. Use of remdesivir for patients with Covid-19: a review article.
32696811 2020. Long-term positive severe acute respiratory syndrome coronavirus 2 ribonucleic acid and therapeutic effect of antivirals in patients with coronavirus disease: Case reports.
32691011 2020. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
32661235 2020. Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development.
32660307 2020. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
32695804 2020. Cellular Therapy: Shafts of Light Emerging for COVID-19.
32698898 2020. Mesenchymal stem cells: current clinical progress in ARDS and COVID-19.
32678017 2020. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.
32696426 2020. Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.
32661867 2020. Mesenchymal Stem Cell Derived Exosomes: a Nano Platform for Therapeutics and Drug Delivery in Combating COVID-19.
32641644 2020. COVID-19 Pandemic: Can Maintaining Optimal Zinc Balance Enhance Host Resistance?
32653199 2020. Immunomodulation for the management of corona virus disease (COVID-19).
32631501 2020. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
32620409 2020. Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.
32694044 2020. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma.
32694043 2020. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.
32684483 2020. A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Framework for Accelerated Synthesis of Trial Evidence-FAST Evidence.
32660611 2020. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
32682360 2020. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data.
32654907 2020. Bacillus Calmette-Guerin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality.
32653276 2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
32620375 2020. Contingent assessment of the COVID-19 vaccine.
32684499 2020. Planning for COVID-19 vaccines safety surveillance.
32698423 2020. Identification and Analysis of Unstructured, Linear B-Cell Epitopes in SARS-CoV-2 Virion Proteins for Vaccine Development.
32664505 2020. Significantly Improved COVID-19 Outcomes in Countries with Higher BCG Vaccination Coverage: A Multivariable Analysis.
32666898 2020. Images in Vascular Medicine: Peripheral artery thrombosis in critically ill patients with COVID-19.
32691699 2020. Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
32696396 2020. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
32698440 2020. Tiotropium is Predicted to be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis.

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis